Thermo Fisher Scientific (TMO) 10-Q 4 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Oct. 01, 2016shares
Document and Entity Information [Abstract]
Entity Registrant Name	Thermo Fisher Scientific Inc.
Entity Central Index Key	97,745
Document Type	10-Q
Document Period End Date	Oct. 1, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	395,025,225
Entity Stock Trading Symbol	TMO

Consolidated Balance Sheet (Una

Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions	Oct. 01, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 1,970	$ 452.1
Accounts receivable, less allowances of $82.3 and $70.1	2,895.1	2,544.9
Inventories	2,390.9	1,991.7
Other current assets	948.4	752.5
Total current assets	8,204.4	5,741.2
Property, Plant and Equipment, Net	2,599.3	2,448.8
Acquisition-related Intangible Assets, Net	14,522.4	12,758.3
Other Assets	1,104.6	1,058.4
Goodwill	21,580	18,827.6
Total Assets	48,010.7	40,834.3
Current Liabilities:
Short-term obligations and current maturities of long-term obligations	1,972.1	1,051.8
Accounts payable	941.7	822.2
Accrued payroll and employee benefits	611.2	598.2
Accrued income taxes	23.7	212.5
Deferred revenue	492.2	317.9
Other accrued expenses	1,219	1,143.7
Total current liabilities	5,259.9	4,146.3
Deferred Income Taxes	2,715	2,622.6
Other Long-term Liabilities	1,436.8	1,295
Long-term Obligations	16,940.4	11,420.2
Shareholders' Equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 414,958,014 and 411,944,301 shares issued	415	411.9
Capital in excess of par value	12,097.1	11,801.2
Retained earnings	13,356.5	12,142.3
Treasury stock at cost, 19,932,789 and 12,314,200 shares	(2,055.3)	(1,007.9)
Accumulated other comprehensive items	(2,154.7)	(1,997.3)
Total shareholders' equity	21,658.6	21,350.2
Total Liabilities and Shareholders' Equity	$ 48,010.7	$ 40,834.3

Consolidated Balance Sheet (Un3

Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($) $ in Millions	Oct. 01, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts Receivable Allowances	$ 82.3	$ 70.1
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$ 100	$ 100
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares)	0	0
Common Stock, $1 Par Value - Par Value (in dollars per share)	$ 1	$ 1
Common Stock, $1 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares)	414,958,014	411,944,301
Treasury Stock at Cost (in shares)	19,932,789	12,314,200

Consolidated Statement of Incom

Consolidated Statement of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015	Oct. 01, 2016	Sep. 26, 2015
Revenues
Product revenues	$ 3,866.5	$ 3,570.3	$ 11,453	$ 10,635.1
Service revenues	624.4	552.9	1,867.9	1,677.8
Total revenues	4,490.9	4,123.2	13,320.9	12,312.9
Costs and Operating Expenses:
Cost of product revenues	2,024.3	1,853.9	5,997.2	5,481.7
Cost of service revenues	412.7	386	1,233.4	1,183.6
Selling, general and administrative expenses	1,274.6	1,133.3	3,710.6	3,421.7
Research and development expenses	183.3	171.6	542.2	512
Restructuring and other costs, net	54.9	15.5	140.9	67.9
Total costs and operating expenses	3,949.8	3,560.3	11,624.3	10,666.9
Operating Income	541.1	562.9	1,696.6	1,646
Other Expense, Net	(113.2)	(94.8)	(324.6)	(292.3)
Income from Continuing Operations Before Income Taxes	427.9	468.1	1,372	1,353.7
Benefit from Income Taxes	45.6	9.2	20.6	20.3
Income from Continuing Operations	473.5	477.3	1,392.6	1,374
Loss from Discontinued Operations (net of income tax benefit of $0.0, $0.7, $0.2 and $0.7)	0	(1.2)	(0.3)	(1.2)
Net Income	$ 473.5	$ 476.1	$ 1,392.3	$ 1,372.8
Earnings per Share from Continuing Operations
Basic (in dollars per share)	$ 1.20	$ 1.20	$ 3.53	$ 3.45
Diluted (in dollars per share)	1.19	1.19	3.50	3.42
Earnings per Share
Basic (in dollars per share)	1.20	1.19	3.53	3.45
Diluted (in dollars per share)	$ 1.19	$ 1.18	$ 3.50	$ 3.42
Weighted Average Shares
Basic (in shares)	394.7	399	394.8	398.4
Diluted (in shares)	397.4	402	397.6	401.7
Cash Dividends Declared per Common Share (in dollars per share)	$ 0.15	$ 0.15	$ 0.45	$ 0.45

Consolidated Statement of Inco5

Consolidated Statement of Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015	Oct. 01, 2016	Sep. 26, 2015
Income Statement [Abstract]
Provision for (Benefit from) Income Taxes on Income (Loss) from Discontinued Operations	$ 0	$ (0.7)	$ (0.2)	$ (0.7)

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015	Oct. 01, 2016	Sep. 26, 2015
Comprehensive Income
Net Income	$ 473.5	$ 476.1	$ 1,392.3	$ 1,372.8
Other Comprehensive Items:
Currency translation adjustment	(77)	(263.6)	(127.8)	(605.6)
Unrealized gains and losses on available-for-sale investments:
Unrealized holding gains (losses) arising during the period (net of tax provision (benefit) of $0.1, ($0.2), ($0.2) and ($0.2))	0.5	(0.2)	(1)	(0.2)
Reclassification adjustment for losses included in net income (net of tax benefit of $0.2 and $0.2)	0.7	0	0.7	0
Unrealized gains and losses on hedging instruments:
Unrealized gains (losses) on hedging instruments (net of tax provision (benefit) of $0.0, ($17.7), ($22.4) and ($3.6))	0	(28.7)	(36.6)	(5.7)
Reclassification adjustment for losses included in net income (net of tax benefit of $1.2, $0.5, $2.6 and $1.1)	1.8	0.6	4.3	2.5
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $0.1, ($0.2), ($0.0) and $1.5)	0	(1)	(1.1)	2.4
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $0.5, $0.7, $1.4 and $1.9)	1.4	1.6	4.1	5.2
Total other comprehensive items	(72.6)	(291.3)	(157.4)	(601.4)
Comprehensive Income	$ 400.9	$ 184.8	$ 1,234.9	$ 771.4

Consolidated Statement of Comp7

Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015	Oct. 01, 2016	Sep. 26, 2015
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on unrealized holding gains and losses on available-for-sale investments arising during the period	$ 0.1	$ (0.2)	$ (0.2)	$ (0.2)
Tax provision (benefit) on reclassification adjustment for gains on available-for-sale investments recognized in net income	(0.2)		(0.2)
Tax provision (benefit) on unrealized holding gains and losses on hedging instruments arising during the period	0	(17.7)	(22.4)	(3.6)
Tax provision (benefit) on reclassification adjustment for losses on hedging instruments recognized in net income	(1.2)	(0.5)	(2.6)	(1.1)
Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period	0.1	(0.2)	0	1.5
Tax provision (benefit) on amortization of net loss and prior service benefit included in net periodic pension cost	$ (0.5)	$ (0.7)	$ (1.4)	$ (1.9)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015
Operating Activities
Net Income	$ 1,392.3	$ 1,372.8
Loss from discontinued operations	0.3	1.2
Income from continuing operations	1,392.6	1,374
Adjustments to reconcile income from continuing operations to net cash provided by operating activities:
Depreciation and amortization	1,284.2	1,263.7
Change in deferred income taxes	(514.8)	(285.9)
Net gains on sale of businesses	0	(7.6)
Non-cash stock-based compensation	102	91.8
Tax benefits from stock-based compensation awards	(54.9)	(55.6)
Non-cash charges for sale of inventories revalued at the date of acquisition	38.7	0.7
Other non-cash expenses, net	49	39.5
Changes in assets and liabilities, excluding the effects of acquisitions and dispositions:
Accounts receivable	(112.4)	(145.9)
Inventories	22.3	(175.3)
Other assets	(92.3)	(213.7)
Accounts payable	66.1	(26.9)
Other liabilities	(194)	(236.3)
Contributions to retirement plans	(33.1)	(25.7)
Net cash provided by continuing operations	1,953.4	1,596.8
Net cash used in discontinued operations	(3)	(8)
Net cash provided by operating activities	1,950.4	1,588.8
Investing Activities
Acquisitions, net of cash acquired	(5,153)	(306)
Purchase of property, plant and equipment	(310.9)	(293.5)
Proceeds from sale of property, plant and equipment	23.1	7.5
Other investing activities, net	(3.2)	16
Net cash used in investing activities	(5,444)	(576)
Financing Activities
Net proceeds from issuance of debt	7,605.8	542.8
Repayment of debt	(2,307.1)	(2,481)
Increase in commercial paper, net	768.8	725.5
Purchases of company common stock	(1,000)	(500)
Dividends paid	(179.2)	(180.7)
Net proceeds from issuance of company common stock under employee stock plans	122.5	96.6
Tax benefits from stock-based compensation awards	54.9	55.6
Other financing activities, net	(13.6)	(5.9)
Net cash provided by (used in) financing activities	5,052.1	(1,747.1)
Exchange Rate Effect on Cash	(40.6)	(105.8)
Increase (Decrease) in Cash and Cash Equivalents	1,517.9	(840.1)
Cash and Cash Equivalents at Beginning of Period	452.1	1,343.5
Cash and Cash Equivalents at End of Period	$ 1,970	$ 503.4

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock [Member]	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]
Balance (in shares) at Dec. 31, 2014		408.5			8
Balance at Dec. 31, 2014	$ 20,548.1	$ 408.5	$ 11,473.6	$ 10,406.9	$ (455.9)	$ (1,285)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)		2.9			0.4
Issuance of shares under employees' and directors' stock plans	64.1	$ 2.9	112.6		$ (51.4)
Stock-based compensation	91.8		91.8
Tax benefit related to employees' and directors' stock plans	54.8		54.8
Purchases of company common stock (in shares)					3.9
Purchases of company common stock	(500)				$ (500)
Dividends declared	(180)			(180)
Net Income	1,372.8			1,372.8
Other comprehensive items	(601.4)					(601.4)
Balance (in shares) at Sep. 26, 2015		411.4			12.3
Balance at Sep. 26, 2015	20,850.2	$ 411.4	11,732.8	11,599.7	$ (1,007.3)	(1,886.4)
Balance (in shares) at Dec. 31, 2015		411.9			12.3
Balance at Dec. 31, 2015	21,350.2	$ 411.9	11,801.2	12,142.3	$ (1,007.9)	(1,997.3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)		3.1			0.3
Issuance of shares under employees' and directors' stock plans	95.4	$ 3.1	139.7		$ (47.4)
Stock-based compensation	102		102
Tax benefit related to employees' and directors' stock plans	54.2		54.2
Purchases of company common stock (in shares)					7.3
Purchases of company common stock	(1,000)				$ (1,000)
Dividends declared	(178.1)			(178.1)
Net Income	1,392.3			1,392.3
Other comprehensive items	(157.4)					(157.4)
Balance (in shares) at Oct. 01, 2016		415			19.9
Balance at Oct. 01, 2016	$ 21,658.6	$ 415	$ 12,097.1	$ 13,356.5	$ (2,055.3)	$ (2,154.7)

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	9 Months Ended
	Oct. 01, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies [Text Block]	Note 1 . Nature of Operations and Summary of Significant Accounting Policies Nature of Operations Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. Interim Financial Statements The interim consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at October 1, 2016 , the results of operations for the three- and nine-month periods ended October 1, 2016 and September 26, 2015 , and the cash flows for the nine-month periods ended October 1, 2016 and September 26, 2015 . Interim results are not necessarily indicative of results for a full year. The consolidated balance sheet presented as of December 31, 2015 , has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The consolidated financial statements and notes included in this report should be read in conjunction with the 2015 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC). Note 1 to the consolidated financial statements for 2015 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the nine months ended October 1, 2016 . Inventories The components of inventories are as follows: October 1, December 31, (In millions) 2016 2015 Raw Materials $ 498.1 $ 421.1 Work in Process 367.3 236.8 Finished Goods 1,525.5 1,333.8 Inventories $ 2,390.9 $ 1,991.7 Property, Plant and Equipment Property, plant and equipment consists of the following: October 1, December 31, (In millions) 2016 2015 Land $ 291.2 $ 276.4 Buildings and Improvements 1,118.6 1,050.5 Machinery, Equipment and Leasehold Improvements 3,055.0 2,786.8 Property, Plant and Equipment, at Cost 4,464.8 4,113.7 Less: Accumulated Depreciation and Amortization 1,865.5 1,664.9 Property, Plant and Equipment, Net $ 2,599.3 $ 2,448.8 Acquisition-related Intangible Assets Acquisition-related intangible assets are as follows: Balance at October 1, 2016 Balance at December 31, 2015 (In millions) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Definite Lived: Customer relationships $ 13,374.8 $ (4,691.1 ) $ 8,683.7 $ 11,844.4 $ (4,086.9 ) $ 7,757.5 Product technology 5,751.6 (2,116.4 ) 3,635.2 4,799.8 (1,819.0 ) 2,980.8 Tradenames 1,486.3 (628.4 ) 857.9 1,316.7 (548.2 ) 768.5 Other 33.8 (33.8 ) — 33.2 (33.0 ) 0.2 20,646.5 (7,469.7 ) 13,176.8 17,994.1 (6,487.1 ) 11,507.0 Indefinite Lived: Tradenames 1,234.8 — 1,234.8 1,234.8 — 1,234.8 In-process research and development 110.8 — 110.8 16.5 — 16.5 1,345.6 — 1,345.6 1,251.3 — 1,251.3 Acquisition-related Intangible Assets $ 21,992.1 $ (7,469.7 ) $ 14,522.4 $ 19,245.4 $ (6,487.1 ) $ 12,758.3 Warranty Obligations The liability for warranties is included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows: Nine Months Ended October 1, September 26, (In millions) 2016 2015 Beginning Balance $ 55.8 $ 57.5 Provision charged to income 68.6 59.9 Usage (64.5 ) (59.0 ) Acquisitions 16.8 0.5 Adjustments to previously provided warranties, net (1.8 ) (2.1 ) Currency translation 0.5 (2.2 ) Ending Balance $ 75.4 $ 54.6 Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2 ) and the ultimate loss from abandoning leases at facilities being exited (Note 14 ). Actual results could differ from those estimates. Recent Accounting Pronouncements In August 2016, the FASB issued new guidance intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The guidance is effective for the company in 2018. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the company’s consolidated statement of cash flows. In March 2016, the FASB issued new guidance which affects the accounting for stock-based compensatio n. The new guidance simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for the company in 2017. Early adoption is permitted. The company expects to adopt this guidance on January 1, 2017. Adoption of this guidance is not expected to have a material impact on the company's consolidated financial statements; however, the impact in any given period will be dependent upon changes in the company's stock price, the volume of employee stock option exercises and the timing of service- and performance-based restricted unit vestings. In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to leases. The guidance is effective for the company in 2019 and must be adopted using a modified retrospective method. Early adoption is permitted. The company is currently evaluating the impact the standard will have on its consolidated financial statements. In January 2016, the FASB issued new guidance which affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. This guidance retains the current accounting for classifying and measuring investments in debt securities and loans, but requires equity investments to be measured at fair value with subsequent changes recognized in net income, except for those accounted for under the equity method or requiring consolidation. The guidance also changes the accounting for investments without a readily determinable fair value and that do not qualify for the practical expedient permitted by the guidance to estimate fair value. A policy election can be made for these investments whereby estimated fair value may be measured at cost and adjusted in subsequent periods for any impairment or changes in observable prices of identical or similar investments. The guidance is effective for the company in 2018. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements. In September 2015, the FASB issued new guidance which eliminates the requirement for an acquirer in a business combination to restate prior period financial statements for measurement period adjustments. The new guidance requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified. The new guidance also sets forth new disclosure requirements related to the adjustments. The guidance is effective for the company in 2016. Adoption of this standard did not have a material impact on the company’s consolidated balance sheet. In July 2015, the FASB issued new guidance which requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance does not apply to inventory that is measured using last-in, first-out (LIFO). The guidance is effective for the company in 2017. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements. In April 2015, the FASB issued new guidance which requires the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability, consistent with the current treatment of debt discounts. The guidance is effective for the company in 2016. As a result of adoption of this standard, debt issuance costs of $55 million were reclassified from other assets to reduce long-term debt as of December 31, 2015. In May 2014, the FASB issued new revenue recognition guidance which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. The new standard also requires significantly expanded disclosures regarding the qualitative and quantitative information of an entity's nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. During the first and second quarters of 2016, the FASB issued additional guidance and clarification relating to identifying performance obligations, assessing collectability, licensing, principal verses agent considerations, sales tax, non-cash consideration, contract modification, disclosures and the handling of completed contracts at transition. The guidance is currently effective for the company in 2018. Early adoption is permitted in 2017. The company expects to adopt this guidance on January 1, 2018. The company is currently evaluating the impact the standard will have on its consolidated financial statements.

Acquisitions

Acquisitions	9 Months Ended
	Oct. 01, 2016
Business Combinations [Abstract]
Acquisitions and Dispositions [Text Block]	Note 2 . Acquisitions The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred. 2016 On September 19, 2016, the company acquired, within the Analytical Instruments segment, FEI Company, a North America-based provider of high-performance electron microscopy, for a total purchase price of $4.08 billion , net of cash acquired. The acquisition strengthens the company's analytical instrument portfolio with the addition of high-end electron microscopes. Revenues of FEI were $930 million in 2015. The purchase price exceeded the fair value of the identifiable net assets and, accordingly, $2.06 billion was allocated to goodwill, approximately $65 million of which is tax deductible. On March 31, 2016, the company acquired, within the Life Sciences Solutions segment, Affymetrix, Inc., a North America-based provider of cellular and genetic analysis products, for a total purchase price of $1.34 billion , net of cash acquired, including the assumption of $254 million of debt. The acquisition expands the company's existing portfolio of antibodies and assays for flow cytometry and single-cell biology applications. Additionally, the acquisition expands the company's genetic analysis portfolio through the addition of microarrays. Revenues of Affymetrix were $360 million in 2015. The purchase price exceeded the fair value of the identifiable net assets and, accordingly, $702 million was allocated to goodwill, none of which is tax deductible. In addition, in 2016, the company acquired, within the Analytical Instruments segment, a provider of X-ray diffraction solutions for material science and industrial applications and, within the Life Sciences Solutions segment, selected assets of an existing channel partner, for an aggregate purchase price of $5 million . During 2016, the company made contingent purchase price payments totaling $1 million for acquisitions completed prior to 2016. The contingent purchase price payments were contractually due to the sellers upon achievement of certain performance criteria at the acquired businesses. The components of the purchase price and net assets acquired for 2016 acquisitions are as follows: (In millions) FEI Affymetrix Other Total Purchase Price Cash paid $ 4,432.8 $ 1,162.2 $ 4.2 $ 5,599.2 Debt assumed — 254.2 0.6 254.8 Purchase price payable 18.4 3.3 0.1 21.8 Cash acquired (369.1 ) (77.9 ) (0.1 ) (447.1 ) $ 4,082.1 $ 1,341.8 $ 4.8 $ 5,428.7 Net Assets Acquired Current assets $ 625.6 $ 160.6 $ 1.1 $ 787.3 Property, plant and equipment 162.6 19.3 — 181.9 Definite-lived intangible assets: Customer relationships 1,051.1 413.2 1.7 1,466.0 Product technology 739.8 232.7 0.7 973.2 Tradenames and other 130.0 41.6 — 171.6 Indefinite-lived intangible assets: In-process research and development 104.7 11.0 — 115.7 Goodwill 2,057.3 702.1 3.1 2,762.5 Other assets 56.5 7.8 0.1 64.4 Liabilities assumed (845.5 ) (246.5 ) (1.9 ) (1,093.9 ) $ 4,082.1 $ 1,341.8 $ 4.8 $ 5,428.7 T he weighted-average amortization periods for definite-lived intangible assets acquired in 2016 are 16 years for customer relationships, 8 years for product technology and 8 years for tradenames and other. The weighted average amortization period for all definite-lived intangible assets acquired in 2016 is 13 years . The preliminary allocation of the purchase price for the 2016 acquisitions was based on estimates of the fair value of the net assets acquired and is subject to adjustment upon finalization of the valuation of the acquired intangible assets in the fourth quarter of 2016. The company recorded a deferred tax liability of $156 million in the acquisition accounting related to the outside basis difference of the Affymetrix Singapore operations as the company does not intend to permanently reinvest the pre-acquisition Singapore earnings. Revenues of FEI in the third quarter of 2016 subsequent to the date of acquisition were approximately $100 million . Operating profits were not material due to acquisition-related charges.

Business Segment Information

Business Segment Information	9 Months Ended
	Oct. 01, 2016
Segment Reporting [Abstract]
Business Segment and Geographical Information [Text Block]	Note 3 . Business Segment Information The company’s financial performance is reported in four segments. A description of each segment follows. Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Analytical Instruments: provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory. Specialty Diagnostics: provides a wide range of diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Services: provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products and an extensive service offering. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory. The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation. Business Segment Information Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions) 2016 2015 2016 2015 Revenues Life Sciences Solutions $ 1,231.5 $ 1,080.4 $ 3,642.1 $ 3,229.6 Analytical Instruments 898.0 778.5 2,451.2 2,282.9 Specialty Diagnostics 798.9 776.9 2,504.8 2,379.2 Laboratory Products and Services 1,746.2 1,638.2 5,273.0 4,844.9 Eliminations (183.7 ) (150.8 ) (550.2 ) (423.7 ) Consolidated revenues 4,490.9 4,123.2 13,320.9 12,312.9 Segment Income (a) Life Sciences Solutions 370.1 332.7 1,069.7 954.9 Analytical Instruments 190.1 146.5 446.7 407.8 Specialty Diagnostics 214.4 204.9 682.4 646.2 Laboratory Products and Services 257.9 249.6 795.9 731.7 Subtotal reportable segments (a) 1,032.5 933.7 2,994.7 2,740.6 Cost of revenues charges (32.4 ) (0.8 ) (60.4 ) (2.5 ) Selling, general and administrative charges, net (62.5 ) (24.6 ) (95.2 ) (35.4 ) Restructuring and other costs, net (54.9 ) (15.5 ) (140.9 ) (67.9 ) Amortization of acquisition-related intangible assets (341.6 ) (329.9 ) (1,001.6 ) (988.8 ) Consolidated operating income 541.1 562.9 1,696.6 1,646.0 Other expense, net (b) (113.2 ) (94.8 ) (324.6 ) (292.3 ) Income from continuing operations before income taxes $ 427.9 $ 468.1 $ 1,372.0 $ 1,353.7 Depreciation Life Sciences Solutions $ 34.1 $ 38.4 $ 108.3 $ 106.7 Analytical Instruments 11.4 9.9 30.9 28.6 Specialty Diagnostics 17.3 18.8 53.5 54.6 Laboratory Products and Services 28.6 30.7 89.9 85.0 Consolidated depreciation $ 91.4 $ 97.8 $ 282.6 $ 274.9 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles. (b) The company does not allocate other expense, net to its segments.

Other Expense, Net

Other Expense, Net	9 Months Ended
	Oct. 01, 2016
Other Income and Expenses [Abstract]
Other Expense, Net [Text Block]	Note 4 . Other Expense, Net The components of other expense, net, in the accompanying statement of income are as follows: Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions) 2016 2015 2016 2015 Interest Income $ 10.4 $ 7.2 $ 34.4 $ 21.9 Interest Expense (113.3 ) (100.6 ) (338.3 ) (311.9 ) Other Items, Net (10.3 ) (1.4 ) (20.7 ) (2.3 ) Other Expense, Net $ (113.2 ) $ (94.8 ) $ (324.6 ) $ (292.3 ) Other Items, Net I n the first nine months of 2016, other items, net includes $22 million of charges related to the amortization of fees paid to obtain bridge financing commitments for the acquisition of FEI (Note 2 ) and $6.5 million of losses on the early extinguishment of debt, offset in part by $4 million of gains on investments. In the first nine months of 2015, other items, net includes costs of $7.5 million associated with entering into interest rate swap arrangements and losses of $6 million for the early extinguishment of debt.

Stock-based Compensation Expens

Stock-based Compensation Expense	9 Months Ended
	Oct. 01, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation Expense [Text Block]	Note 5 . Stock-based Compensation Expense The components of stock-based compensation expense are primarily included in selling, general and administrative expenses and are as follows: Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions) 2016 2015 2016 2015 Stock Option Awards $ 10.4 $ 11.1 $ 31.0 $ 32.4 Restricted Unit Awards 24.5 21.4 71.0 59.4 Total Stock-based Compensation Expense $ 34.9 $ 32.5 $ 102.0 $ 91.8 During the first nine months of 2016 , the company made equity compensation grants to employees consisting of 0.8 million service- and performance-based restricted stock units and options to purchase 1.7 million shares. As of October 1, 2016 , there was $75 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be recognized through 2020 with a weighted average amortization period of 2.3 years . As of October 1, 2016 , there was $137 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is expected to be recognized through 2020 with a weighted average amortization period of 2.0 years .

Pension and Other Postretiremen

Pension and Other Postretirement Benefit Plans	9 Months Ended
	Oct. 01, 2016
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Pension and Other Postretirement Benefit Plans [Text Block]	Note 6 . Pension and Other Postretirement Benefit Plans Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The costs of the postretirement healthcare programs are generally funded on a self-insured and insured-premium basis. The net periodic benefit cost for the company's defined benefit pension plans includes the following components: Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions) 2016 2015 2016 2015 Components of Net Benefit Cost Service cost-benefits earned $ 5.3 $ 7.7 $ 15.8 $ 20.0 Interest cost on benefit obligation 19.1 19.4 58.1 58.1 Expected return on plan assets (19.3 ) (23.4 ) (58.8 ) (70.0 ) Amortization of actuarial net loss 1.9 2.3 5.6 7.0 Amortization of prior service benefit — (0.1 ) (0.1 ) (0.2 ) Settlement/curtailment loss — — — 0.1 Net periodic benefit cost $ 7.0 $ 5.9 $ 20.6 $ 15.0

Income Taxes

Income Taxes	9 Months Ended
	Oct. 01, 2016
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 7 . Income Taxes The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate of 35% to income from continuing operations before provision for income taxes due to the following: Nine Months Ended October 1, September 26, (In millions) 2016 2015 Provision for Income Taxes at Statutory Rate $ 480.2 $ 473.8 Increases (Decreases) Resulting From: Foreign rate differential (189.7 ) (148.9 ) Income tax credits (233.6 ) (241.4 ) Manufacturing deduction (25.5 ) (27.2 ) Singapore tax holiday (14.0 ) (11.5 ) Impact of change in tax laws and apportionment on deferred taxes 0.3 (13.5 ) Nondeductible expenses 6.3 6.9 Tax return reassessments and settlements (41.0 ) (51.0 ) State income taxes, net of federal tax (6.3 ) (4.8 ) Other, net 2.7 (2.7 ) Benefit from income taxes $ (20.6 ) $ (20.3 ) In 2016 , the company implemented tax planning initiatives related to non-U.S. subsidiaries. These non-U.S. subsidiaries incurred foreign tax obligations, and made cash and deemed distributions to the company’s U.S. operations which resulted in no net tax cost. As a result of these distributions, the company benefitted from U.S. foreign tax credits of $114 million , offset in part by additional U.S. income taxes of $40 million on the related foreign income (which reduced the benefit from the foreign rate differential in 2016 ). The foreign tax credits are the result of foreign earnings remitted or deemed remitted to the U.S. during the reporting year and the U.S. treatment of taxes paid in the foreign jurisdictions in the years those profits were originally earned. The company has significant activities in Singapore and has received considerable tax incentives. The local taxing authority granted the company pioneer company status which provides an incentive encouraging companies to undertake activities that have the effect of promoting economic or technological development in Singapore. This incentive equates to a tax exemption on earnings associated with most of the company’s manufacturing activities in Singapore and continues through December 31, 2021 . In 2016 and 2015 , the impact of this tax holiday decreased the annual effective tax rates by 1.0% and 0.8% , respectively, and increased diluted earnings per share by approximately $0.04 and $0.03 , respectively. The company's unrecognized tax benefits increased to $458 million at October 1, 2016 , from $350 million at December 31, 2015 . Of the total increase, $51 million resulted from acquisitions, $43 million resulted from tax planning related to prior years that resulted in amended tax filings and $14 million resulted from the utilization of deferred tax assets.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Oct. 01, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 8 . Earnings per Share Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions except per share amounts) 2016 2015 2016 2015 Income from Continuing Operations $ 473.5 $ 477.3 $ 1,392.6 $ 1,374.0 Loss from Discontinued Operations — (1.2 ) (0.3 ) (1.2 ) Net Income $ 473.5 $ 476.1 $ 1,392.3 $ 1,372.8 Basic Weighted Average Shares 394.7 399.0 394.8 398.4 Plus Effect of: Stock options and restricted units 2.7 3.0 2.8 3.3 Diluted Weighted Average Shares 397.4 402.0 397.6 401.7 Basic Earnings per Share: Continuing operations $ 1.20 $ 1.20 $ 3.53 $ 3.45 Discontinued operations — — — — Basic Earnings per Share $ 1.20 $ 1.19 $ 3.53 $ 3.45 Diluted Earnings per Share: Continuing operations $ 1.19 $ 1.19 $ 3.50 $ 3.42 Discontinued operations — — — — Diluted Earnings per Share $ 1.19 $ 1.18 $ 3.50 $ 3.42 Options to purchase 0.1 million , 3.5 million , 1.8 million and 3.7 million shares of common stock were not included in the computation of diluted earnings per share for the third quarter of 2016 and 2015 and the first nine months of 2016 and 2015 , respectively, because their effect would have been antidilutive.

Debt and Other Financing Arrang

Debt and Other Financing Arrangements	9 Months Ended
	Oct. 01, 2016
Debt Disclosure [Abstract]
Debt and Other Financing Arrangements [Text Block]	Note 9 . Debt and Other Financing Arrangements Effective Interest Rate at October 1, October 1, December 31, (Dollars in millions) 2016 2016 2015 Commercial Paper 1.32 % $ 820.5 $ 49.6 Term Loan 1.70 % 1,950.0 — 2.25% 5-Year Senior Notes, Due 8/15/2016 — 1,000.0 1.30% 3-Year Senior Notes, Due 2/1/2017 1.21 % 900.0 900.0 1.85% 5-Year Senior Notes, Due 1/15/2018 2.01 % 500.0 500.0 Floating Rate 2-Year Senior Notes, Due 8/9/2018 (euro-denominated) 0.15 % 674.1 — 2.15% 3-Year Senior Notes, Due 12/14/2018 2.35 % 450.0 450.0 2.40% 5-Year Senior Notes, Due 2/1/2019 2.59 % 900.0 900.0 6.00% 10-Year Senior Notes, Due 3/1/2020 2.98 % 750.0 750.0 4.70% 10-Year Senior Notes, Due 5/1/2020 4.23 % 300.0 300.0 1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated) 1.61 % 477.5 461.6 5.00% 10-Year Senior Notes, Due 1/15/2021 3.24 % 400.0 400.0 4.50% 10-Year Senior Notes, Due 3/1/2021 3.48 % 1,000.0 1,000.0 3.60% 10-Year Senior Notes, Due 8/15/2021 3.15 % 1,100.0 1,100.0 3.30% 7-Year Senior Notes, Due 2/15/2022 3.43 % 800.0 800.0 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) 2.28 % 561.8 543.1 3.15% 10-Year Senior Notes, Due 1/15/2023 3.31 % 800.0 800.0 3.00% 7-Year Senior Notes Due 4/15/2023 3.18 % 1,000.0 — 4.15% 10-Year Senior Notes, Due 2/1/2024 4.16 % 1,000.0 1,000.0 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,123.5 — 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.09 % 719.0 695.2 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350.0 350.0 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200.0 — 1.375% 12-Year Senior Notes, 9/12/2028 (euro-denominated) 1.46 % 674.1 — 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400.0 400.0 Other 13.7 16.3 Total Borrowings at Par Value 18,864.2 12,415.8 Fair Value Hedge Accounting Adjustments 73.9 6.2 Unamortized Premium, Net 56.5 104.7 Unamortized Debt Issuance Costs (Note 1) (82.1 ) (54.7 ) Total Borrowings at Carrying Value 18,912.5 12,472.0 Less: Short-term Obligations and Current Maturities 1,972.1 1,051.8 Long-term Obligations $ 16,940.4 $ 11,420.2 The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount or amortization of any premium, the amortization of any debt issuance costs and, if applicable, adjustments related to hedging. See Note 12 for fair value information pertaining to the company’s long-term obligations. Credit Facilities In July 2016, the company replaced its existing revolving credit facility with a new facility with a bank group that provides for up to $2.50 billion of unsecured multi-currency revolving credit. The facility expires in July 2021 . The agreement calls for interest at either a LIBOR-based rate, a EURIBOR-based rate (for funds drawn in Euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for financings of this type. The financial covenants require the company to maintain a Consolidated Leverage Ratio of debt to EBITDA (as defined in the agreement) below 4.5 to 1.0 for the first two consecutive quarters after the closing date of the acquisition of FEI (see Note 2), stepping down to 4.0 to 1.0 for the two immediately following fiscal quarters and then stepping down to 3.5 to 1.0 each fiscal quarter thereafter. The agreement also requires the company to maintain an Interest Coverage Ratio of EBITDA (as defined in the agreement) to interest expense of 3.0 to 1.0. The credit agreement permits the company to use the facility for working capital; acquisitions; repurchases of common stock, debentures and other securities; the refinancing of debt; and general corporate purposes. The credit agreement allows for the issuance of letters of credit, which reduces the amount available for borrowing. If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of October 1, 2016 , no borrowings were outstanding under the facility, although available capacity was reduced by approximately $67 million as a result of outstanding letters of credit. Term Loans In connection with the acquisition of FEI, the company entered into a term loan agreement. The term loan agreement is a 3-year unsecured $2.00 billion term loan facility. The agreement calls for interest at either a LIBOR-based rate, a EURIBOR-based rate (for funds drawn under the term loan in Euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreements contain affirmative, negative and financial covenants, and events of default customary for financings of this type. The financial covenants are consistent with those in the revolving credit facility described above. In the first quarter of 2016, in connection with the acquisition of Affymetrix, the company entered into a 364-day $1.00 billion unsecured term loan agreement. In August 2016, the company used the proceeds from the issuance of the floating rate senior notes due 2018 to repay the remaining balance of this term loan. Senior Notes Interest on the floating rate senior notes is payable quarterly. Interest is payable annually on the other euro-denominated senior notes and semi-annually on all other senior notes. Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium plus accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements. In April 2016, the company issued $1.00 billion principal amount of 3.00% Senior Notes due 2023 and used the proceeds to repay all of the 2.25% Senior Notes due 2016. Prior to issuing the 3.00% Senior Notes due 2023, the company had entered into an agreement to hedge its exposure related to the interest rate on the anticipated borrowings (described under the heading " Cash Flow Hedge Arrangements " in Note 12 ) that was terminated in April 2016. The company had a cash outlay of $75 million early in the second quarter of 2016 associated with termination of the arrangement, included in other financing activities, net, in the accompanying statement of cash flows. In August 2016, Thermo Fisher Scientific (Finance I) B.V., a wholly-owned finance subsidiary of the company issued the Floating Rate Senior Notes due 2018 included in the table above. This subsidiary has no independent function other than financing activities. The Floating Rate Senior Notes due 2018 are fully and unconditionally guaranteed by the company and no other subsidiaries of the company have guaranteed the obligations. During the third quarter of 2016, the company issued the 0.75% Senior Notes due 2024, the 2.95% Senior Notes due 2026 and the 1.375% Senior Notes due 2028, included in the table above. The proceeds from these issuances, along with the proceeds from the 3-year unsecured term loan facility described above, were used to fund the acquisition of FEI and, in October 2016, to redeem the 1.30% Senior Notes due 2017. Interest Rate Swap Arrangements In the first quarter of 2016, the company terminated certain of its fixed to floating rate swap arrangements. The terminated swaps were accounted for as fair value hedges. As a result of terminating these arrangements, the company received $61 million (excluding accrued interest) in cash in the second quarter of 2016, included in other financing activities, net, in the accompanying statement of cash flows. The proceeds were recorded as part of the carrying value of the underlying debt and will be amortized as a reduction to interest expense over the remaining terms of the respective debt instruments. Subsequently, the company entered into new swap arrangements which are included in the table below. The company has entered into LIBOR-based interest rate swap arrangements with various banks on several of its outstanding senior notes. The aggregate amounts of the swaps are equal to the principal amounts of the notes and the payment dates of the swaps coincide with the interest payment dates of the notes. The swap contracts provide for the company to pay a variable interest rate and receive a fixed rate. The variable interest rates reset monthly. The swaps have been accounted for as fair value hedges of the notes. See Note 12 for additional information. The following table summarizes the outstanding interest rate swap arrangements on the company's senior notes at October 1, 2016 : Aggregate Notional Amount Pay Rate as of (Dollars in millions) Pay Rate October 1, Receive Rate 1.30% Senior Notes due 2017 $ 900.0 1-month LIBOR + 0.6616% 1.1888 % 1.30 % 4.50% Senior Notes due 2021 1,000.0 1-month LIBOR + 3.4420% 3.9692 % 4.50 % 3.60% Senior Notes due 2021 1,100.0 1-month LIBOR + 2.5150% 3.0393 % 3.60 % 3.00% Senior Notes due 2023 1,000.0 1-month LIBOR + 1.7640% 2.2883 % 3.00 %

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 01, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	Note 10 . Commitments and Contingencies Environmental Matters The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including reports prepared by environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At October 1, 2016 , the company’s total environmental liability was approximately $49 million . While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations or cash flows. Litigation and Related Contingencies There are various lawsuits and claims pending against the company including matters involving product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below or in the company's 2015 Annual Report on Form 10-K filed with the SEC, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows. Product Liability, Workers Compensation and Other Personal Injury Matters For product liability, workers compensation and other personal injury matters, the company accrues the most likely amount or at least the minimum of the range of possible loss when a range of possible loss can be estimated. The company records estimated amounts due from insurers related to certain product liabilities as an asset. Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary materially. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis. Intellectual Property Matters On July 13 and 15, 2015, 454 Life Sciences (a member of the Roche Group) filed complaints against Ion Torrent Systems, Inc., Life Technologies Corp., and Thermo Fisher Scientific Inc. in the United States District Court for the District of Delaware and in Germany. Plaintiff alleges infringement of patents relating to methods of analyzing nucleic acid sequences using emulsion amplification, which plaintiff alleges are impermissibly used in Ion Torrent sequencing workflows. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees and costs, and injunctive relief. On June 6, 2004, Enzo Biochem, Enzo Life Sciences and Yale University filed a complaint against Life Technologies in United States District Court for the District of Connecticut. The plaintiffs allege patent infringement by Applera’s labeled DNA terminator products used in DNA sequencing and fragment analysis. The plaintiff sought damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief. In November 2012, the jury awarded damages of $49 million . Prejudgment interest of $12 million was also granted. The $61 million judgment and interest was accrued by Life Technologies and the liability was assumed by the company as of the date of the acquisition. In March 2015 the United States Court of Appeals for the Federal Circuit vacated the judgment and returned the case to the District Court for further proceedings. In February 2016, the District Court granted the company’s motion for summary judgment of non-infringement and entered judgment in its favor. Enzo appealed that decision to the Federal Circuit in March 2016. The company has maintained the $61 million accrual, pending appeals. On May 26, 2010, Promega Corp. & Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften EV filed a complaint against Life Technologies in the United States District Court for the Western District of Wisconsin. The plaintiffs allege patent infringement by sales and uses of Applied Biosystems’ short tandem repeat DNA identification products outside the scope of a 2006 license agreement. The plaintiff sought damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief. Although a jury initially found willful infringement and assessed damages at $52 million , the District Court subsequently overturned the verdict on the grounds that the plaintiff had failed to prove infringement. The District Court entered judgment in favor of Life Technologies; and plaintiffs and Life Technologies filed cross-appeals with the United States Court of Appeals for the Federal Circuit. The $52 million award was accrued by Life Technologies and the liability was assumed by the company as of the date of the acquisition. On December 15, 2014, the Court of Appeals issued a decision invalidating four of the plaintiffs’ patents, but finding infringement by Life Technologies of the remaining fifth patent. The Court of Appeals also ordered a new trial on damages in the District Court. Life Technologies' petition to the U.S. Supreme Court seeking review of the Court of Appeals’ judgment was granted on June 27, 2016, and the case is stayed in the District Court pending the outcome of the Supreme Court’s review. The company has maintained the $52 million accrual, pending conclusion of this matter. On December 27, 2011, Illumina Inc. filed a complaint against Life Technologies in the United States District Court for the Southern District of California alleging infringement of a patent relating to methods for making bead arrays by Ion Torrent’s semiconductor sequencing systems. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, pre- and post-judgment interest, and injunctive relief. On June 3, 2013, Unisone Strategic IP filed a complaint against Life Technologies in the United States District Court for the Southern District of California alleging patent infringement by Life Technologies’ supply chain management system software, which operates with product “supply centers” installed at customer sites. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, and injunctive relief. Commercial Matters On May 5, 2015, and February 12, 2016, the Academy of Allergy & Asthma in Primary Care and United Biologics, LLC d/b/a United Allergy Services, a provider of on-site services to physicians in the delivery of testing and treatment of allergies, filed a complaint against Phadia U.S. Inc. (a subsidiary of the company) and Thermo Fisher Scientific Inc., respectively, in the United States District Court for the Western District of Texas. The plaintiffs allege various claims of anticompetitive activities in violation of antitrust laws, tortious interference with contracts and existing and prospective business relations, and civil conspiracy. On March 28, 2016, the company filed a counterclaim against United Biologics, LLC alleging tortious interference with business relations and seeking a declaratory judgment and injunctive relief. The plaintiffs seek damages, attorneys’ fees, costs, and injunctive relief.

Comprehensive Income and Shareh

Comprehensive Income and Shareholders Equity	9 Months Ended
	Oct. 01, 2016
Stockholders' Equity Note [Abstract]
Comprehensive Income and Shareholders' Equity [Text Block]	Note 11 . Comprehensive Income and Shareholders' Equity Comprehensive Income (Loss) Comprehensive income (loss) combines net income and other comprehensive items. Other comprehensive items represent certain amounts that are reported as components of shareholders’ equity in the accompanying balance sheet. Changes in each component of accumulated other comprehensive items, net of tax are as follows: (In millions) Currency Unrealized Unrealized Pension and Total Balance at December 31, 2015 $ (1,776.7 ) $ 1.8 $ (26.6 ) $ (195.8 ) $ (1,997.3 ) Other comprehensive income (loss) before reclassifications (127.8 ) (1.0 ) (36.6 ) (1.1 ) (166.5 ) Amounts reclassified from accumulated other comprehensive items — 0.7 4.3 4.1 9.1 Net other comprehensive items (127.8 ) (0.3 ) (32.3 ) 3.0 (157.4 ) Balance at October 1, 2016 $ (1,904.5 ) $ 1.5 $ (58.9 ) $ (192.8 ) $ (2,154.7 )

Fair Value Measurements and Fai

Fair Value Measurements and Fair Value of Financial Instruments	9 Months Ended
	Oct. 01, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements and Fair Value of Financial Instruments [Text Block]	Note 12 . Fair Value Measurements and Fair Value of Financial Instruments Fair Value Measurements The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2016 . The company’s financial assets and liabilities carried at fair value are primarily comprised of insurance contracts, investments in money market funds, derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration. The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves. Level 3: Inputs are unobservable data points that are not corroborated by market data. The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of October 1, 2016 and December 31, 2015 : October 1, Quoted Significant Significant (In millions) 2016 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 851.0 $ 851.0 $ — $ — Bank time deposits 2.0 2.0 — — Investments in mutual funds and other similar instruments 17.3 17.3 — — Warrants 2.8 — 2.8 — Insurance contracts 117.8 — 117.8 — Derivative contracts 27.8 — 27.8 — Total Assets $ 1,018.7 $ 870.3 $ 148.4 $ — Liabilities Derivative contracts $ 11.0 $ — $ 11.0 $ — Contingent consideration 1.0 — — 1.0 Total Liabilities $ 12.0 $ — $ 11.0 $ 1.0 December 31, Quoted Significant Significant (In millions) 2015 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 54.6 $ 54.6 $ — $ — Bank time deposits 2.0 2.0 — — Investments in mutual funds and other similar instruments 7.6 7.6 — — Warrants 3.4 — 3.4 — Insurance contracts 108.1 — 108.1 — Derivative contracts 13.8 — 13.8 — Total Assets $ 189.5 $ 64.2 $ 125.3 $ — Liabilities Derivative contracts $ 41.8 $ — $ 41.8 $ — Contingent consideration 1.9 — — 1.9 Total Liabilities $ 43.7 $ — $ 41.8 $ 1.9 The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company determines the fair value of acquisition-related contingent consideration based on assessment of the probability that the company would be required to make such future payment. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. The notional amounts of derivative contracts outstanding, consisting of interest rate swaps and currency exchange contracts, totaled $8.28 billion and $6.63 billion at October 1, 2016 and December 31, 2015 , respectively. While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheet. The following tables present the fair value of derivative instruments in the consolidated balance sheet and statement of income. Fair Value – Assets Fair Value – Liabilities October 1, December 31, October 1, December 31, (In millions) 2016 2015 2016 2015 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ 13.0 $ 0.2 $ — $ 16.4 Derivatives Not Designated as Hedging Instruments Currency exchange contracts (b) 14.8 13.6 11.0 25.4 (a) The fair value of the interest rate swaps is included in the consolidated balance sheet under the captions other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses. Gain (Loss) Recognized Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions) 2016 2015 2016 2015 Derivatives Designated as Fair Value Hedges Interest rate swaps - effective portion $ 4.9 $ 9.5 $ 17.0 $ 25.7 Interest rate swaps - ineffective portion (a) 1.1 (0.2 ) 1.6 (7.4 ) Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of revenues $ (3.7 ) $ (6.0 ) $ (18.7 ) $ 11.5 Included in other expense, net 1.2 (6.4 ) (42.9 ) 130.6 (a) The ineffective portion of the loss recognized on interest rate swaps during the nine months ended September 26, 2015 includes $7.5 million of costs associated with entering into the swap arrangements. Gains and losses recognized on currency exchange contracts and the effective portion of interest rate swaps are included in the consolidated statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. Gains and losses recognized on the ineffective portion of interest rate swaps are included in other expense, net in the accompanying statement of income. The company also uses foreign currency-denominated debt to partially hedge its net investments in foreign operations against adverse movements in exchange rates. The company’s euro-denominated senior notes have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in currency translation adjustment within other comprehensive income and shareholders’ equity. In the first nine months of 2016 and 2015 , pre-tax net (losses)/gains of $(54) million and $43 million , respectively, from the euro-denominated notes were included in currency translation adjustment. Cash Flow Hedge Arrangements In 2015, the company entered into interest rate swap arrangements to mitigate the risk of interest rates rising prior to completion of a debt offering in 2016. Based on the company’s conclusion that a debt offering was probable as a result of debt maturing in 2016 and that such debt would carry semi-annual interest payments over a 10 -year term, the swaps hedged the cash flow risk for each of the semi-annual fixed-rate interest payments on $1.00 billion of principal amount of the planned fixed-rate debt issue. The change in the fair value of the hedge during 2016 , $37 million , net of tax, was classified as a decrease to accumulated other comprehensive items within shareholders’ equity. The hedge was terminated in advance of completing a debt offering in April 2016 (Note 9). The fair value of the hedge at that time, $46 million , net of tax, was classified as a reduction to accumulated other comprehensive items and is being amortized to interest expense over the term of the debt. Fair Value of Other Financial Instruments The carrying value and fair value of the company’s notes receivable and debt obligations are as follows: October 1, 2016 December 31, 2015 Carrying Fair Carrying Fair (In millions) Value Value Value Value Notes Receivable $ 12.4 $ 14.4 $ 12.1 $ 14.9 Debt Obligations: Senior notes $ 16,132.3 $ 16,816.1 $ 12,406.1 $ 12,618.8 Term loan 1,946.0 1,950.0 — — Commercial paper 820.5 820.5 49.6 49.6 Other 13.7 13.7 16.3 16.3 $ 18,912.5 $ 19,600.3 $ 12,472.0 $ 12,684.7 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Oct. 01, 2016
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information [Text Block]	Note 13 . Supplemental Cash Flow Information Nine Months Ended October 1, September 26, (In millions) 2016 2015 Non-cash Activities Fair value of assets of acquired businesses $ 6,969.7 $ 315.6 Cash paid for acquired businesses (5,599.2 ) (307.6 ) Liabilities assumed of acquired businesses $ 1,370.5 $ 8.0 Declared but unpaid dividends $ 60.2 $ 61.1 Issuance of stock upon vesting of restricted stock units $ 125.2 $ 129.4

Restructuring and Other Costs,

Restructuring and Other Costs, Net	9 Months Ended
	Oct. 01, 2016
Restructuring and Related Activities [Abstract]
Restructuring and Other Costs, Net [Text Block]	Note 14 . Restructuring and Other Costs, Net Restructuring and other costs in the first nine months of 2016 included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, including the closure and consolidation of operations within several facilities in the U.S., Europe and Asia; third-party acquisition transaction and integration costs primarily associated with the acquisitions of FEI and Affymetrix; sales of inventories revalued at the date of acquisition; costs to conform the accounting policies of FEI and Affymetrix with the company's accounting policies; costs to achieve synergies related to acquisitions, including severance and abandoned facility costs; and net charges for litigation matters. These charges were partially offset by gains on sales of real estate. In the first nine months of 2016 , severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the company’s workforce. As of November 4, 2016 , the company has identified restructuring actions that will result in additional charges of approximately $70 million , primarily in 2016 and 2017 , which will be recorded when specified criteria are met, such as communication of benefit arrangements and abandonment of leased facilities. Third Quarter of 2016 During the third quarter of 2016 , the company recorded net restructuring and other costs by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ 10.8 $ 6.2 $ 10.2 $ 27.2 Analytical Instruments 21.6 39.1 30.9 91.6 Specialty Diagnostics — — 11.7 11.7 Laboratory Products and Services — — 1.5 1.5 Corporate — 17.2 0.6 17.8 $ 32.4 $ 62.5 $ 54.9 $ 149.8 The components of net restructuring and other costs by segment are as follows: Life Sciences Solutions In the third quarter of 2016 , the Life Sciences Solutions segment recorded $27.2 million of net restructuring and other charges, including charges to cost of revenues of $10.8 million for sales of inventories revalued at the date of acquisition. The segment also recorded $6.2 million of charges to selling, general and administrative expenses principally for third-party transaction and integration costs related to the acquisition of Affymetrix. In addition, the segment recorded $10.2 million of restructuring and other costs, net, most of which were cash costs associated with headcount reductions and actions to achieve related synergies in the U.S. Analytical Instruments In the third quarter of 2016 , the Analytical Instruments segment recorded $91.6 million of net restructuring and other charges. The segment recorded charges to cost of revenues of $21.6 million , including $16.1 million to conform the accounting policies of FEI with the company's accounting policies and $5.5 million for the sales of inventory revalued at the date of acquisition. The segment recorded $39.1 million of charges to selling, general, and administrative expense, including $30.5 million for third-party transaction costs related to the acquisition of FEI (Note 2 ), as well as $8.5 million to conform the accounting policies of FEI with the company's accounting policies. The segment also recorded $30.9 million of cash restructuring costs, primarily for severance obligations payable to former FEI executives. Specialty Diagnostics In the third quarter of 2016 , the Specialty Diagnostics segment recorded $11.7 million of net restructuring and other costs, including $10.0 million of charges for litigation-related matters, with the remainder principally for severance associated with headcount reductions in Europe. Laboratory Products and Services In the third quarter of 2016 , the Laboratory Products and Services segment recorded $1.5 million of net restructuring and other charges, including $2.2 million of cash restructuring costs primarily for employee severance and other costs associated facility consolidations in the U.S. These cash costs were partially offset by $0.7 million of net gains associated with litigation-related matters of a divested business. Corporate In the third quarter of 2016 , the company recorded $17.8 million of restructuring and other costs, principally within selling, general, and administrative expense, including $17.2 million of charges for product liability litigation. The company also recorded $0.6 million of cash restructuring costs associated with facility consolidation at its corporate operations. First Nine Months of 2016 During the first nine months of 2016 , the company recorded net restructuring and other costs by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ 30.9 $ 32.6 $ 57.4 $ 120.9 Analytical Instruments 21.6 40.9 55.4 117.9 Specialty Diagnostics — — 11.6 11.6 Laboratory Products and Services 7.9 0.5 15.4 23.8 Corporate — 21.2 1.1 22.3 $ 60.4 $ 95.2 $ 140.9 $ 296.5 The components of net restructuring and other costs by segment are as follows: Life Sciences Solutions In the first nine months of 2016 , the Life Sciences Solutions segment recorded $120.9 million of net restructuring and other charges. The segment recorded charges to cost of revenues of $30.9 million , including $27.0 million for sales of inventories revalued at the date of acquisition and $3.9 million to conform the accounting policies of Affymetrix with the company's accounting policies. The segment also recorded $32.6 million of charges to selling, general and administrative expenses, including $30.9 million of third-party transaction and integration costs related to the acquisition of Affymetrix and $3.6 million for accelerated depreciation at facilities closing due to real estate consolidation, which were offset in part by credits of $1.9 million from contingent acquisition consideration. In addition, the segment recorded $62.3 million of cash restructuring costs, including $44.6 million of severance and related costs primarily to achieve acquisition synergies, and $17.7 million of abandoned facilities costs principally for the consolidation of facilities in the U.S. These costs were offset in part by $4.3 million of net gains on litigation-related matters at acquired businesses and $0.6 million of other non-cash income, net. Analytical Instruments In the first nine months of 2016 , the Analytical Instruments segment recorded $117.9 million of net restructuring and other charges. The segment recorded charges to cost of revenues of $21.6 million , including $16.1 million to conform the accounting policies of FEI with the company's accounting policies and $5.5 million for the sales of inventory revalued at the date of acquisition. The segment recorded $40.9 million of charges to selling, general, and administrative expense, including $32.2 million for third-party transaction costs related to the acquisition of FEI, as well as $8.5 million of charges to conform the accounting policies of FEI with the company's accounting policies. The segment also recorded $58.1 million of cash restructuring costs primarily for severance obligations payable to former FEI executives, and charges associated with abandoned facilities, including remediation and other closure costs of a manufacturing facility in the U.S. These costs were offset in part by $2.7 million of gains on the sale of real estate. Specialty Diagnostics In the first nine months of 2016 , the Specialty Diagnostics segment recorded $11.6 million of net restructuring and other charges including $10.0 million of charges for litigation-related matters, as well as $3.7 million of cash restructuring costs for severance and other costs associated with headcount reductions and facility consolidations. These charges were partially offset by $2.1 million of other income, primarily gains on the sale of real estate. Laboratory Products and Services In the first nine months of 2016 , the Laboratory Products and Services segment recorded $23.8 million of net restructuring and other charges. The segment recorded charges to cost of revenues of $7.9 million , including $6.2 million for sales of inventories revalued at the date of acquisition, and $1.7 million for accelerated depreciation at facilities closing due to real estate consolidation. The segment also recorded $0.5 million of charges to selling, general and administrative expenses for accelerated depreciation at facilities closing due to real estate consolidation. The company recorded $10.1 million of cash restructuring costs, primarily for employee severance and other costs associated with headcount reductions and facility consolidations. In addition, the segment recorded $6.8 million of charges for an increase in environmental remediation cost estimates associated with a Superfund site in the U.S., offset in part by $1.3 million of gain on the settlement of litigation. Corporate In the first nine months of 2016 , the company recorded $22.3 million of restructuring and other costs, principally within selling, general, and administrative expenses, including $17.2 million of charges for product liability litigation and $4.0 million of accelerated depreciation on information system to be abandoned due to integration synergies. The segment also recorded $1.5 million of restructuring charges for severance and costs associated with facility consolidation at its corporate operations. These charges were offset in part by $0.4 million of income from the settlement of a retirement plan. The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Severance Abandonment of Excess Facilities Other (a) Total Balance at December 31, 2015 $ 15.2 $ 13.1 $ 3.0 $ 31.3 Costs incurred in 2016 (c) 84.9 43.4 8.5 136.8 Reserves reversed (b) (0.7 ) (0.2 ) (0.2 ) (1.1 ) Payments (36.2 ) (16.6 ) (8.9 ) (61.7 ) Currency translation 0.2 — — 0.2 Balance at October 1, 2016 $ 63.4 $ 39.7 $ 2.4 $ 105.5 (a) Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Represents reductions in cost of plans. (c) Excludes $5.2 million of charges, net, primarily associated with environmental and litigation-related matters and sales of real estate. The company expects to pay accrued restructuring costs as follows: severance, employee-retention obligations and other costs, primarily through 2016 ; and abandoned-facility payments, over lease terms expiring through 2027 .

Nature of Operations and Summ24

Nature of Operations and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 01, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2 ) and the ultimate loss from abandoning leases at facilities being exited (Note 14 ). Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2016, the FASB issued new guidance intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The guidance is effective for the company in 2018. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the company’s consolidated statement of cash flows. In March 2016, the FASB issued new guidance which affects the accounting for stock-based compensatio n. The new guidance simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for the company in 2017. Early adoption is permitted. The company expects to adopt this guidance on January 1, 2017. Adoption of this guidance is not expected to have a material impact on the company's consolidated financial statements; however, the impact in any given period will be dependent upon changes in the company's stock price, the volume of employee stock option exercises and the timing of service- and performance-based restricted unit vestings. In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to leases. The guidance is effective for the company in 2019 and must be adopted using a modified retrospective method. Early adoption is permitted. The company is currently evaluating the impact the standard will have on its consolidated financial statements. In January 2016, the FASB issued new guidance which affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. This guidance retains the current accounting for classifying and measuring investments in debt securities and loans, but requires equity investments to be measured at fair value with subsequent changes recognized in net income, except for those accounted for under the equity method or requiring consolidation. The guidance also changes the accounting for investments without a readily determinable fair value and that do not qualify for the practical expedient permitted by the guidance to estimate fair value. A policy election can be made for these investments whereby estimated fair value may be measured at cost and adjusted in subsequent periods for any impairment or changes in observable prices of identical or similar investments. The guidance is effective for the company in 2018. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements. In September 2015, the FASB issued new guidance which eliminates the requirement for an acquirer in a business combination to restate prior period financial statements for measurement period adjustments. The new guidance requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified. The new guidance also sets forth new disclosure requirements related to the adjustments. The guidance is effective for the company in 2016. Adoption of this standard did not have a material impact on the company’s consolidated balance sheet. In July 2015, the FASB issued new guidance which requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance does not apply to inventory that is measured using last-in, first-out (LIFO). The guidance is effective for the company in 2017. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements. In April 2015, the FASB issued new guidance which requires the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability, consistent with the current treatment of debt discounts. The guidance is effective for the company in 2016. As a result of adoption of this standard, debt issuance costs of $55 million were reclassified from other assets to reduce long-term debt as of December 31, 2015. In May 2014, the FASB issued new revenue recognition guidance which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. The new standard also requires significantly expanded disclosures regarding the qualitative and quantitative information of an entity's nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. During the first and second quarters of 2016, the FASB issued additional guidance and clarification relating to identifying performance obligations, assessing collectability, licensing, principal verses agent considerations, sales tax, non-cash consideration, contract modification, disclosures and the handling of completed contracts at transition. The guidance is currently effective for the company in 2018. Early adoption is permitted in 2017. The company expects to adopt this guidance on January 1, 2018. The company is currently evaluating the impact the standard will have on its consolidated financial statements.

Acquisitions (Policies)

Acquisitions (Policies)	9 Months Ended
	Oct. 01, 2016
Business Combinations [Abstract]
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Nature of Operations and Summ26

Nature of Operations and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Oct. 01, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventories [Table Text Block]	Inventories The components of inventories are as follows: October 1, December 31, (In millions) 2016 2015 Raw Materials $ 498.1 $ 421.1 Work in Process 367.3 236.8 Finished Goods 1,525.5 1,333.8 Inventories $ 2,390.9 $ 1,991.7
Property, Plant and Equipment [Table Text Block]	Property, Plant and Equipment Property, plant and equipment consists of the following: October 1, December 31, (In millions) 2016 2015 Land $ 291.2 $ 276.4 Buildings and Improvements 1,118.6 1,050.5 Machinery, Equipment and Leasehold Improvements 3,055.0 2,786.8 Property, Plant and Equipment, at Cost 4,464.8 4,113.7 Less: Accumulated Depreciation and Amortization 1,865.5 1,664.9 Property, Plant and Equipment, Net $ 2,599.3 $ 2,448.8
Finite-Lived Acquisition-related Intangible Assets [Table Text Block]	Acquisition-related Intangible Assets Acquisition-related intangible assets are as follows: Balance at October 1, 2016 Balance at December 31, 2015 (In millions) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Definite Lived: Customer relationships $ 13,374.8 $ (4,691.1 ) $ 8,683.7 $ 11,844.4 $ (4,086.9 ) $ 7,757.5 Product technology 5,751.6 (2,116.4 ) 3,635.2 4,799.8 (1,819.0 ) 2,980.8 Tradenames 1,486.3 (628.4 ) 857.9 1,316.7 (548.2 ) 768.5 Other 33.8 (33.8 ) — 33.2 (33.0 ) 0.2 20,646.5 (7,469.7 ) 13,176.8 17,994.1 (6,487.1 ) 11,507.0 Indefinite Lived: Tradenames 1,234.8 — 1,234.8 1,234.8 — 1,234.8 In-process research and development 110.8 — 110.8 16.5 — 16.5 1,345.6 — 1,345.6 1,251.3 — 1,251.3 Acquisition-related Intangible Assets $ 21,992.1 $ (7,469.7 ) $ 14,522.4 $ 19,245.4 $ (6,487.1 ) $ 12,758.3
Indefinite-Lived Acquisition-related Intangible Assets [Table Text Block]	Acquisition-related Intangible Assets Acquisition-related intangible assets are as follows: Balance at October 1, 2016 Balance at December 31, 2015 (In millions) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Definite Lived: Customer relationships $ 13,374.8 $ (4,691.1 ) $ 8,683.7 $ 11,844.4 $ (4,086.9 ) $ 7,757.5 Product technology 5,751.6 (2,116.4 ) 3,635.2 4,799.8 (1,819.0 ) 2,980.8 Tradenames 1,486.3 (628.4 ) 857.9 1,316.7 (548.2 ) 768.5 Other 33.8 (33.8 ) — 33.2 (33.0 ) 0.2 20,646.5 (7,469.7 ) 13,176.8 17,994.1 (6,487.1 ) 11,507.0 Indefinite Lived: Tradenames 1,234.8 — 1,234.8 1,234.8 — 1,234.8 In-process research and development 110.8 — 110.8 16.5 — 16.5 1,345.6 — 1,345.6 1,251.3 — 1,251.3 Acquisition-related Intangible Assets $ 21,992.1 $ (7,469.7 ) $ 14,522.4 $ 19,245.4 $ (6,487.1 ) $ 12,758.3
Warranty Obligations [Table Text Block]	Warranty Obligations The liability for warranties is included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows: Nine Months Ended October 1, September 26, (In millions) 2016 2015 Beginning Balance $ 55.8 $ 57.5 Provision charged to income 68.6 59.9 Usage (64.5 ) (59.0 ) Acquisitions 16.8 0.5 Adjustments to previously provided warranties, net (1.8 ) (2.1 ) Currency translation 0.5 (2.2 ) Ending Balance $ 75.4 $ 54.6

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Oct. 01, 2016
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The components of the purchase price and net assets acquired for 2016 acquisitions are as follows: (In millions) FEI Affymetrix Other Total Purchase Price Cash paid $ 4,432.8 $ 1,162.2 $ 4.2 $ 5,599.2 Debt assumed — 254.2 0.6 254.8 Purchase price payable 18.4 3.3 0.1 21.8 Cash acquired (369.1 ) (77.9 ) (0.1 ) (447.1 ) $ 4,082.1 $ 1,341.8 $ 4.8 $ 5,428.7 Net Assets Acquired Current assets $ 625.6 $ 160.6 $ 1.1 $ 787.3 Property, plant and equipment 162.6 19.3 — 181.9 Definite-lived intangible assets: Customer relationships 1,051.1 413.2 1.7 1,466.0 Product technology 739.8 232.7 0.7 973.2 Tradenames and other 130.0 41.6 — 171.6 Indefinite-lived intangible assets: In-process research and development 104.7 11.0 — 115.7 Goodwill 2,057.3 702.1 3.1 2,762.5 Other assets 56.5 7.8 0.1 64.4 Liabilities assumed (845.5 ) (246.5 ) (1.9 ) (1,093.9 ) $ 4,082.1 $ 1,341.8 $ 4.8 $ 5,428.7

Business Segment Information (T

Business Segment Information (Tables)	9 Months Ended
	Oct. 01, 2016
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Business Segment Information Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions) 2016 2015 2016 2015 Revenues Life Sciences Solutions $ 1,231.5 $ 1,080.4 $ 3,642.1 $ 3,229.6 Analytical Instruments 898.0 778.5 2,451.2 2,282.9 Specialty Diagnostics 798.9 776.9 2,504.8 2,379.2 Laboratory Products and Services 1,746.2 1,638.2 5,273.0 4,844.9 Eliminations (183.7 ) (150.8 ) (550.2 ) (423.7 ) Consolidated revenues 4,490.9 4,123.2 13,320.9 12,312.9 Segment Income (a) Life Sciences Solutions 370.1 332.7 1,069.7 954.9 Analytical Instruments 190.1 146.5 446.7 407.8 Specialty Diagnostics 214.4 204.9 682.4 646.2 Laboratory Products and Services 257.9 249.6 795.9 731.7 Subtotal reportable segments (a) 1,032.5 933.7 2,994.7 2,740.6 Cost of revenues charges (32.4 ) (0.8 ) (60.4 ) (2.5 ) Selling, general and administrative charges, net (62.5 ) (24.6 ) (95.2 ) (35.4 ) Restructuring and other costs, net (54.9 ) (15.5 ) (140.9 ) (67.9 ) Amortization of acquisition-related intangible assets (341.6 ) (329.9 ) (1,001.6 ) (988.8 ) Consolidated operating income 541.1 562.9 1,696.6 1,646.0 Other expense, net (b) (113.2 ) (94.8 ) (324.6 ) (292.3 ) Income from continuing operations before income taxes $ 427.9 $ 468.1 $ 1,372.0 $ 1,353.7 Depreciation Life Sciences Solutions $ 34.1 $ 38.4 $ 108.3 $ 106.7 Analytical Instruments 11.4 9.9 30.9 28.6 Specialty Diagnostics 17.3 18.8 53.5 54.6 Laboratory Products and Services 28.6 30.7 89.9 85.0 Consolidated depreciation $ 91.4 $ 97.8 $ 282.6 $ 274.9 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles. (b) The company does not allocate other expense, net to its segments.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Business Segment Information Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions) 2016 2015 2016 2015 Revenues Life Sciences Solutions $ 1,231.5 $ 1,080.4 $ 3,642.1 $ 3,229.6 Analytical Instruments 898.0 778.5 2,451.2 2,282.9 Specialty Diagnostics 798.9 776.9 2,504.8 2,379.2 Laboratory Products and Services 1,746.2 1,638.2 5,273.0 4,844.9 Eliminations (183.7 ) (150.8 ) (550.2 ) (423.7 ) Consolidated revenues 4,490.9 4,123.2 13,320.9 12,312.9 Segment Income (a) Life Sciences Solutions 370.1 332.7 1,069.7 954.9 Analytical Instruments 190.1 146.5 446.7 407.8 Specialty Diagnostics 214.4 204.9 682.4 646.2 Laboratory Products and Services 257.9 249.6 795.9 731.7 Subtotal reportable segments (a) 1,032.5 933.7 2,994.7 2,740.6 Cost of revenues charges (32.4 ) (0.8 ) (60.4 ) (2.5 ) Selling, general and administrative charges, net (62.5 ) (24.6 ) (95.2 ) (35.4 ) Restructuring and other costs, net (54.9 ) (15.5 ) (140.9 ) (67.9 ) Amortization of acquisition-related intangible assets (341.6 ) (329.9 ) (1,001.6 ) (988.8 ) Consolidated operating income 541.1 562.9 1,696.6 1,646.0 Other expense, net (b) (113.2 ) (94.8 ) (324.6 ) (292.3 ) Income from continuing operations before income taxes $ 427.9 $ 468.1 $ 1,372.0 $ 1,353.7 Depreciation Life Sciences Solutions $ 34.1 $ 38.4 $ 108.3 $ 106.7 Analytical Instruments 11.4 9.9 30.9 28.6 Specialty Diagnostics 17.3 18.8 53.5 54.6 Laboratory Products and Services 28.6 30.7 89.9 85.0 Consolidated depreciation $ 91.4 $ 97.8 $ 282.6 $ 274.9 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles. (b) The company does not allocate other expense, net to its segments.

Other Expense, Net (Tables)

Other Expense, Net (Tables)	9 Months Ended
	Oct. 01, 2016
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	The components of other expense, net, in the accompanying statement of income are as follows: Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions) 2016 2015 2016 2015 Interest Income $ 10.4 $ 7.2 $ 34.4 $ 21.9 Interest Expense (113.3 ) (100.6 ) (338.3 ) (311.9 ) Other Items, Net (10.3 ) (1.4 ) (20.7 ) (2.3 ) Other Expense, Net $ (113.2 ) $ (94.8 ) $ (324.6 ) $ (292.3 )

Stockbased Compensation Expense

Stockbased Compensation Expense (Tables)	9 Months Ended
	Oct. 01, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	The components of stock-based compensation expense are primarily included in selling, general and administrative expenses and are as follows: Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions) 2016 2015 2016 2015 Stock Option Awards $ 10.4 $ 11.1 $ 31.0 $ 32.4 Restricted Unit Awards 24.5 21.4 71.0 59.4 Total Stock-based Compensation Expense $ 34.9 $ 32.5 $ 102.0 $ 91.8

Pension and Other Postretirem31

Pension and Other Postretirement Benefit Plans (Tables)	9 Months Ended
	Oct. 01, 2016
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Schedule of Net Benefit Costs [Table Text Block]	The net periodic benefit cost for the company's defined benefit pension plans includes the following components: Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions) 2016 2015 2016 2015 Components of Net Benefit Cost Service cost-benefits earned $ 5.3 $ 7.7 $ 15.8 $ 20.0 Interest cost on benefit obligation 19.1 19.4 58.1 58.1 Expected return on plan assets (19.3 ) (23.4 ) (58.8 ) (70.0 ) Amortization of actuarial net loss 1.9 2.3 5.6 7.0 Amortization of prior service benefit — (0.1 ) (0.1 ) (0.2 ) Settlement/curtailment loss — — — 0.1 Net periodic benefit cost $ 7.0 $ 5.9 $ 20.6 $ 15.0

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Oct. 01, 2016
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate of 35% to income from continuing operations before provision for income taxes due to the following: Nine Months Ended October 1, September 26, (In millions) 2016 2015 Provision for Income Taxes at Statutory Rate $ 480.2 $ 473.8 Increases (Decreases) Resulting From: Foreign rate differential (189.7 ) (148.9 ) Income tax credits (233.6 ) (241.4 ) Manufacturing deduction (25.5 ) (27.2 ) Singapore tax holiday (14.0 ) (11.5 ) Impact of change in tax laws and apportionment on deferred taxes 0.3 (13.5 ) Nondeductible expenses 6.3 6.9 Tax return reassessments and settlements (41.0 ) (51.0 ) State income taxes, net of federal tax (6.3 ) (4.8 ) Other, net 2.7 (2.7 ) Benefit from income taxes $ (20.6 ) $ (20.3 )

Earnings per Share (Tables)

Earnings per Share (Tables)	9 Months Ended
	Oct. 01, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions except per share amounts) 2016 2015 2016 2015 Income from Continuing Operations $ 473.5 $ 477.3 $ 1,392.6 $ 1,374.0 Loss from Discontinued Operations — (1.2 ) (0.3 ) (1.2 ) Net Income $ 473.5 $ 476.1 $ 1,392.3 $ 1,372.8 Basic Weighted Average Shares 394.7 399.0 394.8 398.4 Plus Effect of: Stock options and restricted units 2.7 3.0 2.8 3.3 Diluted Weighted Average Shares 397.4 402.0 397.6 401.7 Basic Earnings per Share: Continuing operations $ 1.20 $ 1.20 $ 3.53 $ 3.45 Discontinued operations — — — — Basic Earnings per Share $ 1.20 $ 1.19 $ 3.53 $ 3.45 Diluted Earnings per Share: Continuing operations $ 1.19 $ 1.19 $ 3.50 $ 3.42 Discontinued operations — — — — Diluted Earnings per Share $ 1.19 $ 1.18 $ 3.50 $ 3.42

Debt and Other Financing Arra34

Debt and Other Financing Arrangements (Tables)	9 Months Ended
	Oct. 01, 2016
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Effective Interest Rate at October 1, October 1, December 31, (Dollars in millions) 2016 2016 2015 Commercial Paper 1.32 % $ 820.5 $ 49.6 Term Loan 1.70 % 1,950.0 — 2.25% 5-Year Senior Notes, Due 8/15/2016 — 1,000.0 1.30% 3-Year Senior Notes, Due 2/1/2017 1.21 % 900.0 900.0 1.85% 5-Year Senior Notes, Due 1/15/2018 2.01 % 500.0 500.0 Floating Rate 2-Year Senior Notes, Due 8/9/2018 (euro-denominated) 0.15 % 674.1 — 2.15% 3-Year Senior Notes, Due 12/14/2018 2.35 % 450.0 450.0 2.40% 5-Year Senior Notes, Due 2/1/2019 2.59 % 900.0 900.0 6.00% 10-Year Senior Notes, Due 3/1/2020 2.98 % 750.0 750.0 4.70% 10-Year Senior Notes, Due 5/1/2020 4.23 % 300.0 300.0 1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated) 1.61 % 477.5 461.6 5.00% 10-Year Senior Notes, Due 1/15/2021 3.24 % 400.0 400.0 4.50% 10-Year Senior Notes, Due 3/1/2021 3.48 % 1,000.0 1,000.0 3.60% 10-Year Senior Notes, Due 8/15/2021 3.15 % 1,100.0 1,100.0 3.30% 7-Year Senior Notes, Due 2/15/2022 3.43 % 800.0 800.0 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) 2.28 % 561.8 543.1 3.15% 10-Year Senior Notes, Due 1/15/2023 3.31 % 800.0 800.0 3.00% 7-Year Senior Notes Due 4/15/2023 3.18 % 1,000.0 — 4.15% 10-Year Senior Notes, Due 2/1/2024 4.16 % 1,000.0 1,000.0 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,123.5 — 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.09 % 719.0 695.2 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350.0 350.0 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200.0 — 1.375% 12-Year Senior Notes, 9/12/2028 (euro-denominated) 1.46 % 674.1 — 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400.0 400.0 Other 13.7 16.3 Total Borrowings at Par Value 18,864.2 12,415.8 Fair Value Hedge Accounting Adjustments 73.9 6.2 Unamortized Premium, Net 56.5 104.7 Unamortized Debt Issuance Costs (Note 1) (82.1 ) (54.7 ) Total Borrowings at Carrying Value 18,912.5 12,472.0 Less: Short-term Obligations and Current Maturities 1,972.1 1,051.8 Long-term Obligations $ 16,940.4 $ 11,420.2
Schedule of Derivative Instruments [Table Text Block]	The following table summarizes the outstanding interest rate swap arrangements on the company's senior notes at October 1, 2016 : Aggregate Notional Amount Pay Rate as of (Dollars in millions) Pay Rate October 1, Receive Rate 1.30% Senior Notes due 2017 $ 900.0 1-month LIBOR + 0.6616% 1.1888 % 1.30 % 4.50% Senior Notes due 2021 1,000.0 1-month LIBOR + 3.4420% 3.9692 % 4.50 % 3.60% Senior Notes due 2021 1,100.0 1-month LIBOR + 2.5150% 3.0393 % 3.60 % 3.00% Senior Notes due 2023 1,000.0 1-month LIBOR + 1.7640% 2.2883 % 3.00 %

Comprehensive Income and Shar35

Comprehensive Income and Shareholders Equity (Tables)	9 Months Ended
	Oct. 01, 2016
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in each component of accumulated other comprehensive items, net of tax are as follows: (In millions) Currency Unrealized Unrealized Pension and Total Balance at December 31, 2015 $ (1,776.7 ) $ 1.8 $ (26.6 ) $ (195.8 ) $ (1,997.3 ) Other comprehensive income (loss) before reclassifications (127.8 ) (1.0 ) (36.6 ) (1.1 ) (166.5 ) Amounts reclassified from accumulated other comprehensive items — 0.7 4.3 4.1 9.1 Net other comprehensive items (127.8 ) (0.3 ) (32.3 ) 3.0 (157.4 ) Balance at October 1, 2016 $ (1,904.5 ) $ 1.5 $ (58.9 ) $ (192.8 ) $ (2,154.7 )

Fair Value Measurements and F36

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	9 Months Ended
	Oct. 01, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of October 1, 2016 and December 31, 2015 : October 1, Quoted Significant Significant (In millions) 2016 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 851.0 $ 851.0 $ — $ — Bank time deposits 2.0 2.0 — — Investments in mutual funds and other similar instruments 17.3 17.3 — — Warrants 2.8 — 2.8 — Insurance contracts 117.8 — 117.8 — Derivative contracts 27.8 — 27.8 — Total Assets $ 1,018.7 $ 870.3 $ 148.4 $ — Liabilities Derivative contracts $ 11.0 $ — $ 11.0 $ — Contingent consideration 1.0 — — 1.0 Total Liabilities $ 12.0 $ — $ 11.0 $ 1.0 December 31, Quoted Significant Significant (In millions) 2015 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 54.6 $ 54.6 $ — $ — Bank time deposits 2.0 2.0 — — Investments in mutual funds and other similar instruments 7.6 7.6 — — Warrants 3.4 — 3.4 — Insurance contracts 108.1 — 108.1 — Derivative contracts 13.8 — 13.8 — Total Assets $ 189.5 $ 64.2 $ 125.3 $ — Liabilities Derivative contracts $ 41.8 $ — $ 41.8 $ — Contingent consideration 1.9 — — 1.9 Total Liabilities $ 43.7 $ — $ 41.8 $ 1.9
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value – Assets Fair Value – Liabilities October 1, December 31, October 1, December 31, (In millions) 2016 2015 2016 2015 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ 13.0 $ 0.2 $ — $ 16.4 Derivatives Not Designated as Hedging Instruments Currency exchange contracts (b) 14.8 13.6 11.0 25.4 (a) The fair value of the interest rate swaps is included in the consolidated balance sheet under the captions other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses.
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	Gain (Loss) Recognized Three Months Ended Nine Months Ended October 1, September 26, October 1, September 26, (In millions) 2016 2015 2016 2015 Derivatives Designated as Fair Value Hedges Interest rate swaps - effective portion $ 4.9 $ 9.5 $ 17.0 $ 25.7 Interest rate swaps - ineffective portion (a) 1.1 (0.2 ) 1.6 (7.4 ) Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of revenues $ (3.7 ) $ (6.0 ) $ (18.7 ) $ 11.5 Included in other expense, net 1.2 (6.4 ) (42.9 ) 130.6 (a) The ineffective portion of the loss recognized on interest rate swaps during the nine months ended September 26, 2015 includes $7.5 million of costs associated with entering into the swap arrangements.
Fair Value, by Balance Sheet Grouping [Table Text Block]	The carrying value and fair value of the company’s notes receivable and debt obligations are as follows: October 1, 2016 December 31, 2015 Carrying Fair Carrying Fair (In millions) Value Value Value Value Notes Receivable $ 12.4 $ 14.4 $ 12.1 $ 14.9 Debt Obligations: Senior notes $ 16,132.3 $ 16,816.1 $ 12,406.1 $ 12,618.8 Term loan 1,946.0 1,950.0 — — Commercial paper 820.5 820.5 49.6 49.6 Other 13.7 13.7 16.3 16.3 $ 18,912.5 $ 19,600.3 $ 12,472.0 $ 12,684.7 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	The carrying value and fair value of the company’s notes receivable and debt obligations are as follows: October 1, 2016 December 31, 2015 Carrying Fair Carrying Fair (In millions) Value Value Value Value Notes Receivable $ 12.4 $ 14.4 $ 12.1 $ 14.9 Debt Obligations: Senior notes $ 16,132.3 $ 16,816.1 $ 12,406.1 $ 12,618.8 Term loan 1,946.0 1,950.0 — — Commercial paper 820.5 820.5 49.6 49.6 Other 13.7 13.7 16.3 16.3 $ 18,912.5 $ 19,600.3 $ 12,472.0 $ 12,684.7 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Inform37

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Oct. 01, 2016
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Nine Months Ended October 1, September 26, (In millions) 2016 2015 Non-cash Activities Fair value of assets of acquired businesses $ 6,969.7 $ 315.6 Cash paid for acquired businesses (5,599.2 ) (307.6 ) Liabilities assumed of acquired businesses $ 1,370.5 $ 8.0 Declared but unpaid dividends $ 60.2 $ 61.1 Issuance of stock upon vesting of restricted stock units $ 125.2 $ 129.4

Restructuring and Other Costs38

Restructuring and Other Costs, Net (Tables)	9 Months Ended
	Oct. 01, 2016
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs [Table Text Block]	During the first nine months of 2016 , the company recorded net restructuring and other costs by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ 30.9 $ 32.6 $ 57.4 $ 120.9 Analytical Instruments 21.6 40.9 55.4 117.9 Specialty Diagnostics — — 11.6 11.6 Laboratory Products and Services 7.9 0.5 15.4 23.8 Corporate — 21.2 1.1 22.3 $ 60.4 $ 95.2 $ 140.9 $ 296.5 During the third quarter of 2016 , the company recorded net restructuring and other costs by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ 10.8 $ 6.2 $ 10.2 $ 27.2 Analytical Instruments 21.6 39.1 30.9 91.6 Specialty Diagnostics — — 11.7 11.7 Laboratory Products and Services — — 1.5 1.5 Corporate — 17.2 0.6 17.8 $ 32.4 $ 62.5 $ 54.9 $ 149.8
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Severance Abandonment of Excess Facilities Other (a) Total Balance at December 31, 2015 $ 15.2 $ 13.1 $ 3.0 $ 31.3 Costs incurred in 2016 (c) 84.9 43.4 8.5 136.8 Reserves reversed (b) (0.7 ) (0.2 ) (0.2 ) (1.1 ) Payments (36.2 ) (16.6 ) (8.9 ) (61.7 ) Currency translation 0.2 — — 0.2 Balance at October 1, 2016 $ 63.4 $ 39.7 $ 2.4 $ 105.5 (a) Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Represents reductions in cost of plans. (c) Excludes $5.2 million of charges, net, primarily associated with environmental and litigation-related matters and sales of real estate.

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Oct. 01, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw Materials	$ 498.1	$ 421.1
Work in Process	367.3	236.8
Finished Goods	1,525.5	1,333.8
Inventories	$ 2,390.9	$ 1,991.7

Property, Plant and Equipment (

Property, Plant and Equipment (Details) - USD ($) $ in Millions	Oct. 01, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	$ 4,464.8	$ 4,113.7
Less: Accumulated Depreciation and Amortization	1,865.5	1,664.9
Property, Plant and Equipment, Net	2,599.3	2,448.8
Land [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	291.2	276.4
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	1,118.6	1,050.5
Machinery, Equipment and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	$ 3,055	$ 2,786.8

Acquisition-related Intangible

Acquisition-related Intangible Assets (Details) - USD ($) $ in Millions	Oct. 01, 2016	Dec. 31, 2015
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	$ 20,646.5	$ 17,994.1
Accumulated Amortization	(7,469.7)	(6,487.1)
Definite-Lived Intangible Assets, Net	13,176.8	11,507
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	1,345.6	1,251.3
Acquisition-related Intangible Assets, Gross	21,992.1	19,245.4
Acquisition-related Intangible Assets, net of Accumulated Amortization	14,522.4	12,758.3
Tradenames [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	1,234.8	1,234.8
In-Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	110.8	16.5
Customer Relationships [Member]
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	13,374.8	11,844.4
Accumulated Amortization	(4,691.1)	(4,086.9)
Definite-Lived Intangible Assets, Net	8,683.7	7,757.5
Product Technology [Member]
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	5,751.6	4,799.8
Accumulated Amortization	(2,116.4)	(1,819)
Definite-Lived Intangible Assets, Net	3,635.2	2,980.8
Tradenames [Member]
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	1,486.3	1,316.7
Accumulated Amortization	(628.4)	(548.2)
Definite-Lived Intangible Assets, Net	857.9	768.5
Other Intangible Assets [Member]
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	33.8	33.2
Accumulated Amortization	(33.8)	(33)
Definite-Lived Intangible Assets, Net	$ 0	$ 0.2

Warranty Obligations (Details)

Warranty Obligations (Details) - USD ($) $ in Millions	9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015
Warranty Obligations [Roll Forward]
Beginning Balance	$ 55.8	$ 57.5
Provision charged to income	68.6	59.9
Usage	(64.5)	(59)
Acquisitions	16.8	0.5
Adjustments to previously provided warranties, net	(1.8)	(2.1)
Currency translation	0.5	(2.2)
Ending Balance	$ 75.4	$ 54.6

Recent Accounting Pronouncement

Recent Accounting Pronouncements (Details) - USD ($) $ in Millions	Oct. 01, 2016	Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt Issuance Costs	$ 82.1	$ 54.7
Accounting Standards Update - Presentation of Debt Issuance Costs [Member] | Other Assets [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt Issuance Costs		(55)
Accounting Standards Update - Presentation of Debt Issuance Costs [Member] | Long-term Debt [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt Issuance Costs		$ 55

Acquisitions Purchase Price (De

Acquisitions Purchase Price (Details) - USD ($)	Sep. 19, 2016	Mar. 31, 2016	Oct. 01, 2016	Sep. 26, 2015	Dec. 31, 2015
Purchase Price
Cash paid			$ 5,599,200,000	$ 307,600,000
Debt Assumed			254,800,000
Purchase Price Payable			21,800,000
Cash acquired			(447,100,000)
Total Purchase Price			5,428,700,000
Net Assets Acquired [Abstract]
Current assets			787,300,000
Property, plant and equipment			181,900,000
Goodwill			2,762,500,000
Other assets			64,400,000
Liabilities assumed			(1,093,900,000)
Total Purchase Price			$ 5,428,700,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)			13 years
Other Information
Purchase Price Paid For Acquisitions Completed In A Prior Year			$ 1,000,000
In-Process Research and Development [Member]
Net Assets Acquired [Abstract]
Indefinite-lived intangible assets			115,700,000
Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets			$ 1,466,000,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)			16 years
Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets			$ 973,200,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)			8 years
Tradenames and other [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets			$ 171,600,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)			8 years
FEI Company [Member]
Purchase Price
Cash paid	$ 4,432,800,000
Purchase Price Payable	18,400,000
Cash acquired	(369,100,000)
Total Purchase Price	4,082,100,000
Net Assets Acquired [Abstract]
Current assets	625,600,000
Property, plant and equipment	162,600,000
Goodwill	2,057,300,000
Other assets	56,500,000
Liabilities assumed	(845,500,000)
Total Purchase Price	4,082,100,000
Other Information
Revenue Reported by Acquired Entity					$ 930,000,000
Goodwill, Expected Tax Deductible Amount	65,000,000
FEI Company [Member] | In-Process Research and Development [Member]
Net Assets Acquired [Abstract]
Indefinite-lived intangible assets	104,700,000
FEI Company [Member] | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets	1,051,100,000
FEI Company [Member] | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets	739,800,000
FEI Company [Member] | Tradenames and other [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets	$ 130,000,000
Affymetrix, Inc. [Member]
Purchase Price
Cash paid		$ 1,162,200,000
Debt Assumed		254,200,000
Purchase Price Payable		3,300,000
Cash acquired		(77,900,000)
Total Purchase Price		1,341,800,000
Net Assets Acquired [Abstract]
Current assets		160,600,000
Property, plant and equipment		19,300,000
Goodwill		702,100,000
Other assets		7,800,000
Liabilities assumed		(246,500,000)
Total Purchase Price		1,341,800,000
Other Information
Revenue Reported by Acquired Entity					$ 360,000,000
Goodwill, Expected Tax Deductible Amount		0
Deferred Tax Liabilities, Undistributed Foreign Earnings		156,000,000
Affymetrix, Inc. [Member] | In-Process Research and Development [Member]
Net Assets Acquired [Abstract]
Indefinite-lived intangible assets		11,000,000
Affymetrix, Inc. [Member] | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets		413,200,000
Affymetrix, Inc. [Member] | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets		232,700,000
Affymetrix, Inc. [Member] | Tradenames and other [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets		$ 41,600,000
Other [Member]
Purchase Price
Cash paid			$ 4,200,000
Debt Assumed			600,000
Purchase Price Payable			100,000
Cash acquired			(100,000)
Total Purchase Price			4,800,000
Net Assets Acquired [Abstract]
Current assets			1,100,000
Goodwill			3,100,000
Other assets			100,000
Liabilities assumed			(1,900,000)
Total Purchase Price			4,800,000
Other [Member] | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets			1,700,000
Other [Member] | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets			$ 700,000

Acquisition Pro Forma Results (

Acquisition Pro Forma Results (Details) $ in Millions	3 Months Ended
	Oct. 01, 2016USD ($)
FEI Company [Member]
Business Acquisition [Line Items]
Revenue of Acquiree(s) since date of acquisition	$ 100

Business Segment Information (D

Business Segment Information (Details) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2016USD ($)	Sep. 26, 2015USD ($)	Oct. 01, 2016USD ($)Segment	Sep. 26, 2015USD ($)
Segment Reporting [Abstract]
Number of Reportable Segments | Segment				4
Segment Reporting Information [Line Items]
Revenues		$ 4,490.9	$ 4,123.2	$ 13,320.9	$ 12,312.9
Cost of revenues charges		(32.4)		(60.4)
Selling, general and administrative charges, net		(62.5)		(95.2)
Restructuring and other costs, net		(54.9)	(15.5)	(140.9)	(67.9)
Operating Income		541.1	562.9	1,696.6	1,646
Other expense, net		(113.2)	(94.8)	(324.6)	(292.3)
Income from Continuing Operations Before Income Taxes		427.9	468.1	1,372	1,353.7
Depreciation		91.4	97.8	282.6	274.9
Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges		(10.8)		(30.9)
Selling, general and administrative charges, net		(6.2)		(32.6)
Restructuring and other costs, net		(10.2)		(57.4)
Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges		(21.6)		(21.6)
Selling, general and administrative charges, net		(39.1)		(40.9)
Restructuring and other costs, net		(30.9)		(55.4)
Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Restructuring and other costs, net		(11.7)		(11.6)
Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges				(7.9)
Selling, general and administrative charges, net				(0.5)
Restructuring and other costs, net		(1.5)		(15.4)
Total Reportable Segments [Member]
Segment Reporting Information [Line Items]
Operating Income	[1]	1,032.5	933.7	2,994.7	2,740.6
Total Reportable Segments [Member] | Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Revenues		1,231.5	1,080.4	3,642.1	3,229.6
Operating Income	[1]	370.1	332.7	1,069.7	954.9
Depreciation		34.1	38.4	108.3	106.7
Total Reportable Segments [Member] | Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Revenues		898	778.5	2,451.2	2,282.9
Operating Income	[1]	190.1	146.5	446.7	407.8
Depreciation		11.4	9.9	30.9	28.6
Total Reportable Segments [Member] | Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues		798.9	776.9	2,504.8	2,379.2
Operating Income	[1]	214.4	204.9	682.4	646.2
Depreciation		17.3	18.8	53.5	54.6
Total Reportable Segments [Member] | Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Revenues		1,746.2	1,638.2	5,273	4,844.9
Operating Income	[1]	257.9	249.6	795.9	731.7
Depreciation		28.6	30.7	89.9	85
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues		(183.7)	(150.8)	(550.2)	(423.7)
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges		(32.4)	(0.8)	(60.4)	(2.5)
Selling, general and administrative charges, net		(62.5)	(24.6)	(95.2)	(35.4)
Restructuring and other costs, net		(54.9)	(15.5)	(140.9)	(67.9)
Amortization of acquisition-related intangible assets		$ (341.6)	$ (329.9)	$ (1,001.6)	$ (988.8)
[1]	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

Other Expense, Net (Details)

Other Expense, Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015	Oct. 01, 2016	Sep. 26, 2015
Other Income and Expenses [Abstract]
Interest Income	$ 10.4	$ 7.2	$ 34.4	$ 21.9
Interest Expense	(113.3)	(100.6)	(338.3)	(311.9)
Other Items, Net	(10.3)	(1.4)	(20.7)	(2.3)
Other Expense, Net	$ (113.2)	$ (94.8)	(324.6)	(292.3)
Costs associated with entering into interest rate swap arrangements				7.5
Losses on Extinguishment of Debt			6.5	$ 6
Gain on Sale of Investments			4
Fees Associated with Short-term Financing Commitments			$ 22

Stockbased Compensation Expen48

Stockbased Compensation Expense (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015	Oct. 01, 2016	Sep. 26, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Awards	$ 10.4	$ 11.1	$ 31	$ 32.4
Restricted Unit Awards	24.5	21.4	71	59.4
Stock-based Compensation Expense	34.9	$ 32.5	$ 102	$ 91.8
RSU Granted			0.8
Options Granted			1.7
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Compensation Costs On Nonvested Awards	75		$ 75
Unrecognized Compensation Costs On Nonvested Awards, Weighted Average Period Of Recognition			2 years 4 months
Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Compensation Costs on Nonvested Awards, Period of Recognition			4 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Compensation Costs On Nonvested Awards	$ 137		$ 137
Unrecognized Compensation Costs On Nonvested Awards, Weighted Average Period Of Recognition			2 years
Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Compensation Costs on Nonvested Awards, Period of Recognition			4 years

Pensions Net Benefit Cost (Deta

Pensions Net Benefit Cost (Details) - Pension Plans, Defined Benefit [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015	Oct. 01, 2016	Sep. 26, 2015
Components of Net Periodic Benefit Cost (Income) [Abstract]
Service cost-benefits earned	$ 5.3	$ 7.7	$ 15.8	$ 20
Interest cost on benefit obligation	19.1	19.4	58.1	58.1
Expected return on plan assets	(19.3)	(23.4)	(58.8)	(70)
Amortization of actuarial net loss	1.9	2.3	5.6	7
Amortization of prior service benefit		(0.1)	(0.1)	(0.2)
Settlement/curtailment loss				0.1
Net periodic benefit cost	$ 7	$ 5.9	$ 20.6	$ 15

Income Taxes Rate Reconciliatio

Income Taxes Rate Reconciliation (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015	Oct. 01, 2016	Sep. 26, 2015
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Federal Statutory Income Tax Rate			35.00%	35.00%
Provision for Income Taxes at Statutory Rate			$ 480.2	$ 473.8
Foreign rate differential			(189.7)	(148.9)
Income tax credits			(233.6)	(241.4)
Manufacturing deduction			(25.5)	(27.2)
Singapore tax holiday			(14)	(11.5)
Impact of change in tax laws and apportionment on deferred taxes			0.3	(13.5)
Nondeductible expenses			6.3	6.9
Tax return reassessments and settlements			(41)	(51)
State income taxes, net of federal tax			(6.3)	(4.8)
Other, net			2.7	(2.7)
Benefit from income taxes	$ (45.6)	$ (9.2)	(20.6)	$ (20.3)
US foreign tax credits generated by repatriation of foreign earnings			114
US Income taxes on repatriated foreign earnings			$ 40
Singapore
Income Tax Holiday [Line Items]
Income Tax Holiday, Termination Date			12/31/2021
Effective Income Tax Rate Reconciliation, Tax Holiday, Percent			1.00%	0.80%
Income Tax Holiday, Income Tax Benefits Per Share			$ 0.04	$ 0.03

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) $ in Millions	9 Months Ended
	Oct. 01, 2016USD ($)
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at beginning of year	$ 350
Additions due to acquisitions	51
Balance at end of year	458
Tax planning related to prior years that resulted in amended returns [Member]
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Additions for tax positions of prior years	43
Utilization of Deferred Tax Assets [Member]
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Additions for tax positions of prior years	$ 14

EPS Calculation (Details)

EPS Calculation (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015	Oct. 01, 2016	Sep. 26, 2015
Earnings Per Share [Abstract]
Income from Continuing Operations	$ 473.5	$ 477.3	$ 1,392.6	$ 1,374
Loss from Discontinued Operations	0	(1.2)	(0.3)	(1.2)
Net Income	$ 473.5	$ 476.1	$ 1,392.3	$ 1,372.8
Basic Weighted Average Shares	394.7	399	394.8	398.4
Effect of Stock Options and Restricted Units	2.7	3	2.8	3.3
Diluted Weighted Average Shares	397.4	402	397.6	401.7
Basic Earnings per Share:
Continuing operations (in dollars per share)	$ 1.20	$ 1.20	$ 3.53	$ 3.45
Discontinued operations (in dollars per share)	0	0	0	0
Basic Earnings Per Share (in dollars per share)	1.20	1.19	3.53	3.45
Diluted Earnings per Share:
Continuing operations (in dollars per share)	1.19	1.19	3.50	3.42
Discontinued operations (in dollars per share)	0	0	0	0
Diluted Earnings Per Share (in dollars per share)	$ 1.19	$ 1.18	$ 3.50	$ 3.42
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Stock Options Excluded From Computation Of Earnings Per Share	0.1	3.5	1.8	3.7

Debt Outstanding Debt (Details)

Debt Outstanding Debt (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
	Apr. 30, 2016	Jul. 02, 2016	Oct. 01, 2016	Sep. 26, 2015	Dec. 31, 2015
Debt Instrument [Line Items]
Total Borrowings at Par Value			$ 18,864.2		$ 12,415.8
Fair Value Hedge Accounting Adjustments			73.9		6.2
Unamortized Premium, Net			56.5		104.7
Unamortized Debt Issuance Costs			(82.1)		(54.7)
Total Borrowings at Carrying Value			18,912.5		12,472
Less: Short-term Obligations and Current Maturities			1,972.1		1,051.8
Long-term Obligations			16,940.4		11,420.2
Net proceeds from issuance of debt			7,605.8	$ 542.8
Repayments of Debt			$ 2,307.1	$ 2,481
Payments for Hedge, Financing Activities		$ 75
U.S. Commercial Paper Program [Member]
Debt Instrument [Line Items]
Effective Interest Rate			1.32%
Total Borrowings at Par Value			$ 820.5		49.6
Total Borrowings at Carrying Value			820.5		49.6
Term Loan [Member]
Debt Instrument [Line Items]
Total Borrowings at Carrying Value			$ 1,946
Term Loan [Member] | Unsecured Term Loan 3-Year [Member]
Debt Instrument [Line Items]
Effective Interest Rate			1.70%
Total Borrowings at Par Value			$ 1,950
Senior Notes [Member]
Debt Instrument [Line Items]
Total Borrowings at Carrying Value			$ 16,132.3		12,406.1
Debt Instrument, Call Feature			Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium plus accrued interest.
Senior Notes [Member] | 2.25% 5-Year Senior Notes, Due 8/15/2016 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			2.25%
Debt Instrument, Term			5 years
Debt Instrument, Maturity Date			Aug. 15, 2016
Total Borrowings at Par Value					1,000
Repayments of Debt	$ 1,000
Senior Notes [Member] | 1.30% 3-Year Senior Notes, Due 2/1/2017 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			1.30%
Debt Instrument, Term			3 years
Debt Instrument, Maturity Date			Feb. 1, 2017
Effective Interest Rate			1.21%
Total Borrowings at Par Value			$ 900		900
Senior Notes [Member] | 1.85% 5-Year Senior Notes, Due 1/15/2018 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			1.85%
Debt Instrument, Term			5 years
Debt Instrument, Maturity Date			Jan. 15, 2018
Effective Interest Rate			2.01%
Total Borrowings at Par Value			$ 500		500
Senior Notes [Member] | Floating Rate 2-Year Senior Notes Due 8/9/2018 (euro-denominated) [Member]
Debt Instrument [Line Items]
Debt Instrument, Term			2 years
Debt Instrument, Maturity Date			Aug. 9, 2018
Effective Interest Rate			0.15%
Total Borrowings at Par Value			$ 674.1
Senior Notes [Member] | 2.15% 3-Year Senior Notes, Due 12/14/2018 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			2.15%
Debt Instrument, Term			3 years
Debt Instrument, Maturity Date			Dec. 14, 2018
Effective Interest Rate			2.35%
Total Borrowings at Par Value			$ 450		450
Senior Notes [Member] | 2.40% 5-Year Senior Notes, Due 2/1/2019 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			2.40%
Debt Instrument, Term			5 years
Debt Instrument, Maturity Date			Feb. 1, 2019
Effective Interest Rate			2.59%
Total Borrowings at Par Value			$ 900		900
Senior Notes [Member] | 6.00% 10-Year Senior Notes, Due 3/1/2020 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			6.00%
Debt Instrument, Term			10 years
Debt Instrument, Maturity Date			Mar. 1, 2020
Effective Interest Rate			2.98%
Total Borrowings at Par Value			$ 750		750
Senior Notes [Member] | 4.70% 10-Year Senior Notes, Due 5/1/2020 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			4.70%
Debt Instrument, Term			10 years
Debt Instrument, Maturity Date			May 1, 2020
Effective Interest Rate			4.23%
Total Borrowings at Par Value			$ 300		300
Senior Notes [Member] | 1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate			1.50%
Debt Instrument, Term			5 years
Debt Instrument, Maturity Date			Dec. 1, 2020
Effective Interest Rate			1.61%
Total Borrowings at Par Value			$ 477.5		461.6
Senior Notes [Member] | 5.00% 10-Year Senior Notes, Due 1/15/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			5.00%
Debt Instrument, Term			10 years
Debt Instrument, Maturity Date			Jan. 15, 2021
Effective Interest Rate			3.24%
Total Borrowings at Par Value			$ 400		400
Senior Notes [Member] | 4.50% 10-Year Senior Notes, Due 3/1/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			4.50%
Debt Instrument, Term			10 years
Debt Instrument, Maturity Date			Mar. 1, 2021
Effective Interest Rate			3.48%
Total Borrowings at Par Value			$ 1,000		1,000
Senior Notes [Member] | 3.60% 10-Year Senior Notes, Due 8/15/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			3.60%
Debt Instrument, Term			10 years
Debt Instrument, Maturity Date			Aug. 15, 2021
Effective Interest Rate			3.15%
Total Borrowings at Par Value			$ 1,100		1,100
Senior Notes [Member] | 3.30% 7-Year Senior Notes, Due 2/15/2022 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			3.30%
Debt Instrument, Term			7 years
Debt Instrument, Maturity Date			Feb. 15, 2022
Effective Interest Rate			3.43%
Total Borrowings at Par Value			$ 800		800
Senior Notes [Member] | 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate			2.15%
Debt Instrument, Term			7 years
Debt Instrument, Maturity Date			Jul. 21, 2022
Effective Interest Rate			2.28%
Total Borrowings at Par Value			$ 561.8		543.1
Senior Notes [Member] | 3.15% 10-Year Senior Notes, Due 1/15/2023 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			3.15%
Debt Instrument, Term			10 years
Debt Instrument, Maturity Date			Jan. 15, 2023
Effective Interest Rate			3.31%
Total Borrowings at Par Value			$ 800		800
Senior Notes [Member] | 3.00% 7-Year Senior Notes, Due 4/15/2023 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			3.00%
Debt Instrument, Term			7 years
Debt Instrument, Maturity Date			Apr. 15, 2023
Effective Interest Rate			3.18%
Total Borrowings at Par Value			$ 1,000
Net proceeds from issuance of debt	$ 1,000
Senior Notes [Member] | 4.15% 10-Year Senior Notes, Due 2/1/2024 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			4.15%
Debt Instrument, Term			10 years
Debt Instrument, Maturity Date			Feb. 1, 2024
Effective Interest Rate			4.16%
Total Borrowings at Par Value			$ 1,000		1,000
Senior Notes [Member] | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate			0.75%
Debt Instrument, Term			8 years
Debt Instrument, Maturity Date			Sep. 12, 2024
Effective Interest Rate			0.94%
Total Borrowings at Par Value			$ 1,123.5
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate			2.00%
Debt Instrument, Term			10 years
Debt Instrument, Maturity Date			Apr. 15, 2025
Effective Interest Rate			2.09%
Total Borrowings at Par Value			$ 719		695.2
Senior Notes [Member] | 3.65% 10-Year Senior Notes, Due 12/15/2025 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			3.65%
Debt Instrument, Term			10 years
Debt Instrument, Maturity Date			Dec. 15, 2025
Effective Interest Rate			3.77%
Total Borrowings at Par Value			$ 350		350
Senior Notes [Member] | 2.95% 10-Year Senior Notes, Due 9/19/2026 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			2.95%
Debt Instrument, Term			10 years
Debt Instrument, Maturity Date			Sep. 19, 2026
Effective Interest Rate			3.19%
Total Borrowings at Par Value			$ 1,200
Senior Notes [Member] | 1.375% 12-Year Senior Notes, 9/12/2028 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate			1.375%
Debt Instrument, Term			12 years
Debt Instrument, Maturity Date			Sep. 12, 2028
Effective Interest Rate			1.46%
Total Borrowings at Par Value			$ 674.1
Senior Notes [Member] | 5.30% 30-Year Senior Notes, Due 2/1/2044 [Member]
Debt Instrument [Line Items]
Stated Interest Rate			5.30%
Debt Instrument, Term			30 years
Debt Instrument, Maturity Date			Feb. 1, 2044
Effective Interest Rate			5.37%
Total Borrowings at Par Value			$ 400		400
Other Debt [Member]
Debt Instrument [Line Items]
Total Borrowings at Par Value			13.7		16.3
Total Borrowings at Carrying Value			$ 13.7		$ 16.3

Debt Short-term Financing (Deta

Debt Short-term Financing (Details)	9 Months Ended
	Oct. 01, 2016USD ($)	Apr. 02, 2016USD ($)
Revolving Credit Facility [Member]
Short-term Financing [Line Items]
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA	4.5
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA, Third and Fourth Quarter After Acquisition	4
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA, Beginning in the Fifth Quarter After Acquisition	3.5
Maximum Borrowing Capacity	$ 2,500,000,000
Line of Credit Facility, Expiration Date	Jul. 1, 2021
Letters of Credit Outstanding, Amount	$ 67,000,000
Line of Credit Facility, Amount Outstanding	0
Term Loan [Member] | 3-Year Unsecured Term Loan [Member]
Short-term Financing [Line Items]
Maximum Borrowing Capacity	$ 2,000,000,000
Term Loan [Member] | 364-day Unsecured Term Loan [Member]
Short-term Financing [Line Items]
Maximum Borrowing Capacity		$ 1,000,000,000

Debt, Interest Rate Swap Arrang

Debt, Interest Rate Swap Arrangements (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 02, 2016	Oct. 01, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Proceeds from Hedge, Financing Activities	$ 61
Notional Amount Of Derivatives		$ 8,280	$ 6,630
Senior Notes [Member] | 1.30% Senior Notes Due 2017 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 900
Interest Rate Swap, Pay Rate Spread above One-month LIBOR		0.6616%
Interest Rate Swap, Pay Rate at Period End		1.1888%
Interest Rate Swap, Fixed Receive Rate		1.30%
Senior Notes [Member] | 4.50% Senior Notes Due 2021 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 1,000
Interest Rate Swap, Pay Rate Spread above One-month LIBOR		3.442%
Interest Rate Swap, Pay Rate at Period End		3.9692%
Interest Rate Swap, Fixed Receive Rate		4.50%
Senior Notes [Member] | 3.60% Senior Notes Due 2021 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 1,100
Interest Rate Swap, Pay Rate Spread above One-month LIBOR		2.515%
Interest Rate Swap, Pay Rate at Period End		3.0393%
Interest Rate Swap, Fixed Receive Rate		3.60%
Senior Notes [Member] | 3.00% Senior Notes Due 2023 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 1,000
Interest Rate Swap, Pay Rate Spread above One-month LIBOR		1.764%
Interest Rate Swap, Pay Rate at Period End		2.2883%
Interest Rate Swap, Fixed Receive Rate		3.00%

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	Feb. 03, 2014	Nov. 30, 2012	Oct. 01, 2016
Accrual for Environmental Loss Contingencies Disclosure [Abstract]
Accrual for Environmental Loss Contingencies, Net			$ 49
Enzo Biochem, Enzo Life Sciences and Yale Univ [Member]
Loss Contingency [Abstract]
Loss Contingency Accrued			61
Enzo Biochem, Enzo Life Sciences and Yale Univ [Member] | Life Technologies Corporation [Member]
Loss Contingency [Abstract]
Damages Awarded		$ 49
Prejudgment Interest Awarded		$ 12
Loss Contingency Accrued	$ 61
Promega Corp and Max-Plank-Gesellschaft [Member]
Loss Contingency [Abstract]
Loss Contingency Accrued			$ 52
Promega Corp and Max-Plank-Gesellschaft [Member] | Life Technologies Corporation [Member]
Loss Contingency [Abstract]
Damages Awarded	52
Loss Contingency Accrued	$ 52

Comprehensive Income and Shar57

Comprehensive Income and Shareholders' Equity (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015	Oct. 01, 2016	Sep. 26, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			$ 21,350.2	$ 20,548.1
Other comprehensive income (loss) before reclassifications			(166.5)
Amounts reclassified from accumulated other comprehensive items			9.1
Total other comprehensive items	$ (72.6)	$ (291.3)	(157.4)	(601.4)
Balance	21,658.6	20,850.2	21,658.6	20,850.2
Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(1,776.7)
Other comprehensive income (loss) before reclassifications			(127.8)
Total other comprehensive items			(127.8)
Balance	(1,904.5)		(1,904.5)
Unrealized Gains on Available-for-Sale Investments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			1.8
Other comprehensive income (loss) before reclassifications			(1)
Amounts reclassified from accumulated other comprehensive items			0.7
Total other comprehensive items			(0.3)
Balance	1.5		1.5
Unrealized Losses on Hedging Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(26.6)
Other comprehensive income (loss) before reclassifications			(36.6)
Amounts reclassified from accumulated other comprehensive items			4.3
Total other comprehensive items			(32.3)
Balance	(58.9)		(58.9)
Pension and Other Postretirement Benefit Liability Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(195.8)
Other comprehensive income (loss) before reclassifications			(1.1)
Amounts reclassified from accumulated other comprehensive items			4.1
Total other comprehensive items			3
Balance	(192.8)		(192.8)
Accumulated Other Comprehensive Items [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(1,997.3)	(1,285)
Total other comprehensive items			(157.4)	(601.4)
Balance	$ (2,154.7)	$ (1,886.4)	$ (2,154.7)	$ (1,886.4)

Fair Value Measurements, Assets

Fair Value Measurements, Assets and Liabilities (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	Oct. 01, 2016	Dec. 31, 2015
Assets [Abstract]
Cash equivalents	$ 851	$ 54.6
Bank time deposits	2	2
Investments in mutual funds and other similar instruments	17.3	7.6
Warrants	2.8	3.4
Insurance contracts	117.8	108.1
Derivative contracts	27.8	13.8
Total Assets	1,018.7	189.5
Liabilities [Abstract]
Derivative contracts	11	41.8
Contingent consideration	1	1.9
Total Liabilities	12	43.7
Quoted Prices in Active Markets (Level I) [Member]
Assets [Abstract]
Cash equivalents	851	54.6
Bank time deposits	2	2
Investments in mutual funds and other similar instruments	17.3	7.6
Total Assets	870.3	64.2
Significant Other Observable Inputs (Level 2) [Member]
Assets [Abstract]
Warrants	2.8	3.4
Insurance contracts	117.8	108.1
Derivative contracts	27.8	13.8
Total Assets	148.4	125.3
Liabilities [Abstract]
Derivative contracts	11	41.8
Total Liabilities	11	41.8
Significant Unobservable Inputs (Level 3) [Member]
Liabilities [Abstract]
Contingent consideration	1	1.9
Total Liabilities	$ 1	$ 1.9

Fair Value Measurements, Deriva

Fair Value Measurements, Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Oct. 01, 2016	Dec. 31, 2015
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value	$ 13	$ 0.2
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value		16.4
Foreign Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value	14.8	13.6
Foreign Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value	$ 11	$ 25.4

Fair Value Measurements, Deri60

Fair Value Measurements, Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015	Oct. 01, 2016	Sep. 26, 2015		Apr. 30, 2016	Dec. 31, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Costs associated with entering into interest rate swap arrangements				$ 7.5
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge			$ (54)	43
Notional Amount Of Derivatives	$ 8,280		8,280				$ 6,630
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax	0	$ (28.7)	(36.6)	(5.7)
Foreign Currency Exchange Contracts [Member] | Cost of Sales [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Effective Portion of Gain (Loss) on Derivative, Net	(3.7)	(6)	(18.7)	11.5
Foreign Currency Exchange Contracts [Member] | Other Expense [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Effective Portion of Gain (Loss) on Derivative, Net	1.2	(6.4)	(42.9)	130.6
Fair Value Hedging [Member] | Interest Rate Swaps [Member] | Other Expense [Member] | Derivatives Designated as Fair Value Hedges [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Effective Portion of Gain (Loss) on Derivative, Net	4.9	9.5	17	25.7
Ineffective Portion of Gain (Loss) on Derivative, Net	$ 1.1	$ (0.2)	$ 1.6	$ (7.4)	[1]
Cash Flow Hedging [Member] | Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt Instrument, Term			10 years
Notional Amount Of Derivatives						$ 1,000
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax						$ (46)
[1]	The ineffective portion of the loss recognized on interest rate swaps during the nine months ended September 26, 2015 includes $7.5 million of costs associated with entering into the swap arrangements.

Fair Value of Other Instruments

Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Oct. 01, 2016	Dec. 31, 2015
Other Financial Instruments [Abstract]
Notes Receivable - Carrying Value	$ 12.4	$ 12.1
Notes Receivable - Fair Value	14.4	14.9
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	18,912.5	12,472
Debt Instrument, Fair Value Disclosure	19,600.3	12,684.7
Senior Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	16,132.3	12,406.1
Debt Instrument, Fair Value Disclosure	16,816.1	12,618.8
Term Loan [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	1,946
Debt Instrument, Fair Value Disclosure	1,950
U.S. Commercial Paper Program [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	820.5	49.6
Debt Instrument, Fair Value Disclosure	820.5	49.6
Other Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	13.7	16.3
Debt Instrument, Fair Value Disclosure	$ 13.7	$ 16.3

Supplemental Cash Flow Inform62

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	9 Months Ended
	Oct. 01, 2016	Sep. 26, 2015
Non-cash Activities [Abstract]
Fair value of assets of acquired businesses	$ 6,969.7	$ 315.6
Cash paid for acquired businesses	(5,599.2)	(307.6)
Liabilities assumed of acquired businesses	1,370.5	8
Declared but unpaid dividends	60.2	61.1
Issuance of stock upon vesting of restricted stock units	$ 125.2	$ 129.4

Restructuring and Other Costs63

Restructuring and Other Costs, Net (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2016	Sep. 26, 2015	Oct. 01, 2016	Sep. 26, 2015	Nov. 04, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Percentage of Total Workforce Eliminated				2.00%
Cost of Revenues		$ 32.4		$ 60.4
Selling, General and Administrative Expenses		62.5		95.2
Restructuring and Other Costs, Net		54.9	$ 15.5	140.9	$ 67.9
Total Restructuring and Other Costs (Income), Net		149.8		296.5
Restructuring and Related Costs, Cash Costs	[1]			136.8
Restructuring and Related Costs, Other Costs (Income), Net				5.2
Loss (Gain) on Divestiture of Businesses				0	$ (7.6)
Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs				84.9
Abandonment of Excess Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs				43.4
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs				8.5
Life Sciences Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues		10.8		30.9
Selling, General and Administrative Expenses		6.2		32.6
Restructuring and Other Costs, Net		10.2		57.4
Total Restructuring and Other Costs (Income), Net		27.2		120.9
Restructuring and Related Costs, Cash Costs				62.3
Restructuring and Related Costs, Other Costs (Income), Net				(0.6)
Loss (Gain) Related to Litigation-related Matter				(4.3)
Life Sciences Solutions [Member] | Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs				44.6
Life Sciences Solutions [Member] | Abandonment of Excess Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs				17.7
Life Sciences Solutions [Member] | Transaction Costs Related to Acquisition [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses				30.9
Life Sciences Solutions [Member] | Contingent Acquisition Consideration [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses				(1.9)
Life Sciences Solutions [Member] | Costs to Conform Accounting Policies [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues				3.9
Life Sciences Solutions [Member] | Charges for Sales of Inventories Revalued at Acquisition [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues				27
Life Sciences Solutions [Member] | Accelerated Depreciation Related to Facility Consolidations [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses				3.6
Analytical Instruments [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues		21.6		21.6
Selling, General and Administrative Expenses		39.1		40.9
Restructuring and Other Costs, Net		30.9		55.4
Total Restructuring and Other Costs (Income), Net		91.6		117.9
Restructuring and Related Costs, Cash Costs		30.9		58.1
Loss (Gain) on Disposition of Property Plant Equipment				(2.7)
Analytical Instruments [Member] | Transaction Costs Related to Acquisition [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		30.5		32.2
Analytical Instruments [Member] | Costs to Conform Accounting Policies [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues		16.1		16.1
Selling, General and Administrative Expenses		8.5		8.5
Analytical Instruments [Member] | Charges for Sales of Inventories Revalued at Acquisition [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues		5.5		5.5
Specialty Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Other Costs, Net		11.7		11.6
Total Restructuring and Other Costs (Income), Net		11.7		11.6
Restructuring and Related Costs, Cash Costs				3.7
Restructuring and Related Costs, Other Costs (Income), Net				(2.1)
Loss (Gain) Related to Litigation-related Matter		10		10
Laboratory Products and Services [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues				7.9
Selling, General and Administrative Expenses				0.5
Restructuring and Other Costs, Net		1.5		15.4
Total Restructuring and Other Costs (Income), Net		1.5		23.8
Restructuring and Related Costs, Cash Costs		2.2		10.1
Loss (Gain) Related to Litigation-related Matter		(0.7)		(1.3)
Laboratory Products and Services [Member] | Environmental Restoration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Other Costs, Net				6.8
Laboratory Products and Services [Member] | Charges for Sales of Inventories Revalued at Acquisition [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues				6.2
Laboratory Products and Services [Member] | Accelerated Depreciation Related to Facility Consolidations [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues				1.7
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		17.2		21.2
Restructuring and Other Costs, Net		0.6		1.1
Total Restructuring and Other Costs (Income), Net		17.8		22.3
Restructuring and Related Costs, Cash Costs		0.6		1.5
Loss (Gain) due to Pension Plan Settlements and Curtailments				(0.4)
Corporate [Member] | Product Liability, Workers Compensation and Other Personal Injury Matters [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		$ 17.2		17.2
Corporate [Member] | Accelerated Depreciation Related to Facility Consolidations [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses				$ 4
Scenario, Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Identified Future Restructuring Costs						$ 70
[1]	Excludes $5.2 million of charges, net, primarily associated with environmental and litigation-related matters and sales of real estate.

Restructuring Reserves (Details

Restructuring Reserves (Details) $ in Millions	9 Months Ended
	Oct. 01, 2016USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 31.3
Costs incurred	136.8	[1]
Reserves reversed	(1.1)
Payments	(61.7)
Currency translation	0.2
Ending balance	105.5
Restructuring and Related Costs, Other Costs (Income), Net	5.2
Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	15.2
Costs incurred	84.9
Reserves reversed	(0.7)
Payments	(36.2)
Currency translation	0.2
Ending balance	$ 63.4
Restructuring Reserve, Expected Final Year of Payments	2,016
Abandonment of Excess Facilities [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	$ 13.1
Costs incurred	43.4
Reserves reversed	(0.2)
Payments	(16.6)
Ending balance	$ 39.7
Restructuring Reserve, Expected Final Year of Payments	2,027
Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	$ 3
Costs incurred	8.5
Reserves reversed	(0.2)
Payments	(8.9)
Ending balance	$ 2.4
Restructuring Reserve, Expected Final Year of Payments	2,016
[1]	Excludes $5.2 million of charges, net, primarily associated with environmental and litigation-related matters and sales of real estate.